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POPULAR SCIENCE ABSTRACT 
 
 
HOW A BONE ENZYME HELPS CANCER CELLS TO SPREAD IN THE BODY 
 
A bone enzyme that could reveal the risk for the spreading of cancer. Research has 
identified that the enzyme TRAP changes the program of cancer cells. This causes them 
to be more aggressive and potentially spread to other sites of the body (´metastasis´). 
Using this knowledge, we could reduce the risk of death by inhibiting the cancer´s 
invasion of our body. 
 
Cancer is an abnormal growth of cells - cells that have changed their genetic information and 
their way of communicating. Thereby, they gradually become aggressive by overcoming all 
safety checks in our body. When cancer cells start to spread in the body (´metastasize´), a 
patient has a high risk of dying. According to statistics, only one out of ten patients wins the 
fight against the uncontrolled disease when diagnosed with metastases. Even though many 
cancers can be treated nowadays, one of the remaining big challenges of research is to 
understand why a cancer starts spreading. 
TRAP makes cancer cells more aggressive 
Research has recently made an important finding that could help us come one molecule closer 
to understanding why and how cancer cells can spread. The enzyme TRAP that is usually 
involved in rebuilding bone is also highly active in cancer cells that have metastasized - a fact 
that supports the assumption that the enzyme is most likely a helper for cancer cell spreading. 
Concomitantly, the main question for this doctoral thesis was: ´What is TRAP doing in cancer 
cells and how can we inhibit it from doing so?´ - To address these questions, the scientists 
imitated the process seen in patients. They genetically modified cancer cells to produce high 
amounts of TRAP. These cells were then used in experimental studies to look at how they 
behave and how TRAP communicates within the cell.  
The outcome was both interesting but also highly concerning. Cancer cells that have a 
specific form of TRAP that has high enzyme activity can both grow and move quicker but 
also pass barriers more easily. These phenomena are described as features of cancer cells, 
which are more aggressive, and increase their potential for spreading. ´But how did the cells 
do that?´ - Therefore, the researchers looked at ´proteomics data´, a method to catalog all 
proteins, protein changes and connections within the cells. These data showed that TRAP 
redirects the communication with other molecules in the cell in a manner, different from how 
cells without TRAP do. Interestingly, when this communication was blocked, certain features 
of the cancer cells normalized, i.e. the cells moved more slowly again. 
Small molecule inhibitors to reprogram cancer cells 
To be able to understand further, how the enzyme TRAP makes cancer cells more aggressive 
and moving, the scientists used small molecule inhibitors. These are drug-like compounds 
that can specifically shut down the activity of TRAP and thereby could reprogram the cells to 
become less aggressive again. Additionally to a previously reported inhibitor, the researchers 
ii 
looked into a big library of chemical compounds and found several other candidates that 
could be used to inhibit TRAP. When cells with high TRAP activity were treated with these 
compounds, they also moved more slowly again.  
Finding compounds that are specific for TRAP can be used to resolve the role of TRAP also 
in other diseases, such as diseases of the bone. Finally, this discovery can assist us in 
predicting, which cancers are at risk to spread and threaten a patient´s life. Using small 
molecule inhibitors for TRAP has a potential use in the development of drugs that could 
eventually be applied in the treatment of patients with diseases involving TRAP. 
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ABSTRACT 
 
Cancer patients diagnosed with metastasis have an increased risk of dying. To be able to 
predict and target tumors with an increased risk for spreading, underlying molecular 
events need to be better dissected and understood.  
TRAP is a metalloenzyme existing in two isoforms - a precursor form (TRAP 5a) and a 
highly enzymatically active form (TRAP 5b). TRAP expression was detected in cancer cells 
of several primary and metastatic tumors and expression levels were raised with increasing 
malignancy. TRAP expression was further correlated to clinical parameters of aggressiveness 
such as reduced tumor- and metastasis-free survival. Underlying molecular processes remain 
unclear and only a limited amount of studies is addressing the respective role of the TRAP 
isoforms in cancer. 
In this thesis, two major milestones were addressed tackling the role of TRAP (isoforms) in 
cancer cell metastasis. (I) Identification and characterization of previously reported and novel 
small molecule inhibitors of TRAP (II) Characterization of functional alterations and cellular 
mechanisms induced by TRAP perturbation.  
The TRAP inhibitor 5-phenylnicotinic acid (5-PNA/CD13) was previously identified by 
fragment-based screening. In Paper I, 5-PNA was further characterized for its ability to 
inhibit the mammalian TRAP, its selectivity for TRAP and its cytotoxicity in a cellular 
model. TRAP-dependent migration was inhibited by 5-PNA, shown to be selective for the 
TRAP 5b isoform. 
By small molecule screening of a library containing drug-like compounds in Paper II, several 
inhibitors for TRAP activity were found and selected based on a strict filtration strategy. 
Orthogonal validation, full-concentration responses and isoform selectivity were assessed for 
a selection of hit compounds. Six potential lead structures were characterized for molecular 
docking modes. The compound CBK289001 rendered valid as inhibiting TRAP-dependent 
migration in a cell system and initial structure-activity relationships were derived. 
The aggressiveness of cancer cells with perturbations of TRAP expression was assessed by 
functional studies in Paper III. TRAP had a promotive effect on cancer cell elongation, 
proliferation, migration and invasion. Proteomics and Phospho-proteomics outlined changes 
in the cellular network associated with extracellular matrix modulation and cell adhesion, and 
a regulation of TGFβ and CD44 signaling. A list of potential TRAP substrates was generated. 
The role of TRAP 5b isoform in cancer cell aggressiveness and Cathepsin K (CtsK) in its 
generation and processing was investigated in Paper IV. TRAP 5b was significantly 
increased compared to TRAP 5a in cells overexpressing TRAP. Inhibition of CtsK, an 
enzyme shown to be able to cleave TRAP, resulted in an intermediate processed TRAP 5b 
form with similar activity and promotive effect on migration. CtsK colocalized highly with 
TRAP 5b and cleaving changed the subcellular localization of TRAP 5b.  
In summary, the work presented in this thesis is contributing to the knowledge about the role 
of TRAP in cancer metastasis. Specifically, we were able to show a connection of TRAP 5b 
to metastasis-related cell functions and the involvement of TGFβ/CD44 signaling. Possible 
starting points for the development of potent and TRAP-specific inhibitors are provided. 
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I PREFACE 
 
 
People all around us are being diagnosed with diseases, treated, cured - sometimes they die, 
sometimes they suffer. Every person around us is in either way affected - everybody knows 
somebody that knows somebody. One out of three individuals will eventually be diagnosed 
with cancer. 
Cancer is an intimidating disease that intersects everybody´s life at some point and it is often 
stigmatized with anticipations. People have lost family members to it; cancer leaves patients 
and their relatives generally with a feeling of lost influence and helplessness. It is not 
surprising that the first reactions after the diagnosis of cancer usually involve questions, such 
as ´What does that mean?´ or ´Can I be treated? ´  
For a variety of diseases science has made such a great progress that going to the pharmacy, 
being treated in a medical facility, taking medication once a week, being able to continue a 
normal life, has become an expectation that cannot be taken for granted. Not always is there a 
golden standard of treatment. Not always is there a good prognosis to be cured or even to 
survive.  
Only due to laborious effort, persistent, creative and devoted scientists and medical doctors, 
we have nowadays reached those crucial breakthroughs and acquired that necessary 
information allowing for a better understanding of the disease, for the identification of new 
treatment strategies and for providing the optimal care of every specific patient.  
Nevertheless, we are still missing pivotal puzzle pieces and need further research to create 
majorly missing knowledge about mechanisms that often lead to a poor prognosis. 
 
´Every field in medicine has had a moment in history that has been transforming. The 
moment, where the knowledge that was required to change the field became available.´ 
Dr. José Baselga, Memorial Sloan Kettering Cancer center 
In Ken Burns CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman.  
 
This is where I see the framework of my thesis to set in - a seemingly little puzzle piece in the 
big picture - a puzzle piece that might for every now and then be underrated in its 
significance. In the end, this work is built upon the strong belief that creating basic 
knowledge about molecular mechanisms and treatment strategies eventually will result in the 
success of beating cancer - by providing just that one little puzzle piece that fits together in 
the big picture. 
 
Inspired by Siddhartha Mukherjee’s 2010 Pulitzer Prize-winning book, ´The Emperor of All 
Maladies: A Biography of Cancer.´ 
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II BACKGROUND 
 
 Cancer 1
 Definition and Epidemiology  1.1
Cancer is a generic term for a group of complex diseases, commonly also termed as 
malignant tumor or neoplasm. The disease is based on the abnormal development and growth 
of cells, leading to outgrowth and spreading into distant sites. Failed treatment or late 
detection of cancer will finally lead to general organ failure, ultimately resulting in the death 
of the patient. 
Cancer is attributable for being one of the leading causes of deaths in the world with 
approximately 14.1 million new cases and 8.2 million deaths in 2012 [1]. The most common 
types are represented by cancers of the lung (1.82 million), breast (1.67 million), and colon 
(1.36 million), whereas the most common causes of cancer death are lung cancer (1.6 million 
deaths), liver cancer (745,000 deaths) and stomach cancer (723,000 deaths) [1]. Accounting 
for more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the 
second most important cause of death and morbidity in Europe [2]. Importantly,  30-50% of 
cancer can be prevented through prevention programs and by early diagnosis [3]. 
 History 1.2
Already 3000 years before Christ, cancer was for the first time described in an ancient 
Egyptian text book, elaborating on eight ulcers of the breast being removed by surgical 
procedures, however incurable [4]. Only from much later, though, we have proof that the 
disease was given a name – around 460–370 before Christ, Hippocrates, the “father of 
medicine”, described and created drawings of the disease he termed “carcinos/carcinoma”. 
Hippocrates applied the latter naming, as the tumor reminded him of a crab, with veins 
stretched on all sides of the body of the tumor [4,5]. Only with the description of the cellular 
theory and the discovery of cellular pathology by Robert Virchow in the 19th
 
century  
(“omnis cellula e cellula”) [6], diseases were no longer diagnosed merely based on symptoms 
but could be defined by anatomical changes. Finally, by the finding of the chemical structure 
of DNA in the 20th century, gene mutations and repair mechanisms of the cell, cancer 
scientists have understood that cancer is a disease that originates from modulations of our 
gene material [4]. These DNA changes can be caused by cancerogenic agents, such as 
physical (e.g. radiation), chemical (e.g. asbestos, components of tobacco smoke or dietary 
habits) and biological carcinogens (e.g. viruses and bacteria) [3]. Next to inherited and 
environmental factors as the reason for cancer-driving mutations, a recent study claimed that 
one third of cancer driver mutations would be due to unavoidable DNA replicative errors [7]. 
In light of this, early detection would claim an even bigger role in patient care. 
Early treatment attempts mainly relied on the removal of the cancer, a strategy that has 
remained applicable until the current days of clinical practice. With the detection of X-rays 
and radioactive elements by Wilhelm Conrad Roentgen and Marie and Pierre Curie in the 
19th century, radiation therapy was put in the spotlight of cancer treatment. Chemotherapy 
was invented in the course of World War II experiments, as several alkylating agents, such as 
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nitrogen mustard [8] proofed to kill rapidly replicating cells via DNA damage allowing for 
the targeting of small cancer masses, unable to be surgically removed. For instance, 
aminopterin, a precursor of the nowadays commonly applied chemotherapeutic methotrexate, 
showed to induce remission in children with acute leukemia [9]. These findings provided the 
basis for novel and more directed chemo-guided strategies that are nowadays applied for a 
more patient-specific treatment. For example, several efforts have been funneled into the 
development of combination chemotherapy, drug delivery techniques, multi-resistance 
treatments and chemoprotective treatments. Given the increasingly better understanding of 
cancer biology, the latest strategies of cancer treatment include immunotherapeutics or 
targeted therapies, such as T-cell therapy, anti-cancer vaccines or antibody-mediated therapy 
[4]. 
 Cancer biology 1.3
 Tumor-Suppressor genes and Proto-Oncogenes  1.3.1
Cell growth is under physiological conditions highly regulated at the molecular level, and 
several regulatory machineries are involved in repairing dysregulated events. During cancer 
development, these machineries can be either rescinded or get dysfunctional, or even 
overridden by promotional forces. Accompanying the findings of genes, scientists introduced 
the terms of tumor-suppressor genes and proto-oncogenes in the 1970s. Tumor-suppressor 
genes and proto-oncogenes are genes encoding for proteins that are involved in the regulation 
of cell division that either lose their suppressor activity or promote the progression of cancer, 
when mutated [5]. They are defined as commonly belonging to either class of growth factors 
(I), growth factor receptors (II), signal transduction proteins (III), transcription factors (IV), 
pro- or anti-apoptotic proteins (V), cell cycle control proteins (VI) or DNA-repair proteins 
(VII). Whereas mutations of one allele of a gene were reported to be sufficient to change a 
proto-oncogene into an oncogene, mutations in both alleles were thought to be necessary to 
drive cancer in the case of a tumor-suppressor gene (two-hit hypothesis) [10]. Nevertheless, 
the current theory of a tumor evolving is manifested on a sequential accumulation of 
mutations in several genes, as suggested in the early 1990s for the development of colorectal 
cancer by Bert Vogelstein [11,12]. 
 Cancer hallmarks: Invasion and Metastasis 1.3.2
In 2006, Hanahan and Weinberg have suggested a framework for the classification of 
capabilities of cancer during the transformation from a normal cell to a malignant one [13] – 
the “hallmarks of cancer”. These alterations of normal cell physiology represented by most 
types of cancers have been termed as (I) self-sufficiency in growth signals, (II) insensitivity 
to growth-inhibitory (antigrowth) signals, (III) evasion of programmed cell death (apoptosis), 
(IV) limitless replicative potential, (V) sustained angiogenesis, and (VI) tissue invasion and 
metastasis. Later, in 2011, these hallmarks have been updated and completed with a second 
generation of enabling and emerging hallmarks [14]. The additional hallmarks, (VII) genome 
instability and mutation, (VIII) tumor-promoting inflammation, (IX) avoiding immune 
destruction and (X) deregulation of cellular energetics were then added to the conceptual 
framework [14].  
Oncogenic mechanisms and inhibitors of TRAP 
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When cancer cells acquire respective traits allowing for tissue invasion and metastasis, most 
cancers ultimately render incurable and lead to the death of the patient. Specifically, most of 
the currently reported deaths of cancer are associated with the development of metastases, as 
current strategies of treatment are not able to completely abrogate or inhibit this process [3].  
Similar principles with regard to the hallmarks of cancer have been earlier conceptualized 
with the description of the stages of metastatic progression. Here, Gupta and Massagué [15] 
described the different traits a cancer cell has to accommodate on its way to the metastatic 
site. A simplistic two-step description of these would be the (I) physical dissemination of the 
primary cancer cells to distant sites, and the (II) adaptation of these cells to the environment 
at the metastatic site. Several concepts important for cancer invasion and metastasis to 
overcome the obstacles barring metastasis have been addressed and are organized by a 
complex network of extracellular and intracellular signals and mechanisms. These include 
e.g. the concept of stem cells and dormancy, cellular heterogeneity of a tumor mass, the 
evolvement of mechanisms to overcome intrinsic and extrinsic barriers (hypoxia, nutritional 
limitations, physical forces, anoikis and senescence programs), the recruitment of tumor-
promoting mesenchyme and inflammatory cells, stromal crosstalk, the ´angiogenic switch´ 
and homing of disseminated cancer cells and hematopoietic progenitor cells.  
As relevant in relation to the research covered in this thesis, specific concepts are pointed out 
based on the summaries and interpretations of Hanahan and Gupta [14,15]. 
 Epithelial-mesenchymal plasticity 1.3.2.1
Both during the initial step of dissemination, intravasation, and when reaching a potential 
metastatic site, cells undergo a transition between an epithelial and mesenchymal state. The 
initial epithelial-to-mesenchymal transition (EMT) is a program that resembles processes 
associated with embryonic morphogenesis and wound healing [16]. A set of transcription 
factors and effector proteins has been postulated as markers of EMT that are induced by cells 
exposed to either the tumoral or the stromal microenvironment. Amongst them, proteins 
associated to increased mobility, cell adhesion molecules and matrix-degrading enzymes are 
part of the signature in cells undergoing EMT [14]. Nevertheless, it has been postulated that 
the same cells need to either be in a temporal state of mesenchymal plasticity or undergo 
partial EMT (hybrid) to be able to colonize metastatic sites (Figure 1) [17].  
 Extracellular matrix modulation 1.3.2.2
Primary cells need to be able to get invasive to overcome barriers, such as the basement 
membrane, a dense network of glycoproteins and proteoglycans and endothelial cell 
structures or when they proceed through the adjacent matrix in the primary and metastatic site 
[14]. The matrix provides the tumor with a variety of growth factors and cytokines that, when 
extracted, can promote tumoral progression. Matrix proteases, such as urokinase-type 
plasminogen activator (uPA) and matrix metalloproteases (MMPs) can be either expressed by 
cancer cells or promoting stromal cells to assist in the degradation and modulation of the 
surrounding matrix [13] during in situ invasion or homing at the metastatic site. As several 
tumor types showed a tendency to metastasize to specific secondary sites (Paget´s “seed-and-
soil hypothesis”, [18]), it was postulated that the cellular program of the metastasizing cells is 
either already adapted to the metastatic site or that soluble factors promote the 
homing/tropism and precondition of the metastatic niche. Here, e.g. premetastatic induction 
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Figure 1 In response to EMT-promoting signals, a subpopulation of epithelial cells at the invasive edge of 
the tumor may lose epithelial traits. As these cells detach from the bulk of the tumor, they become less 
exposed to epithelial signals and acquire mesenchymal properties in the presence of EMT signals supplied 
by stromal cells. A fully mesenchymal phenotype facilitates invasion into surrounding tissues and 
intravasation into blood capillaries or draining lymphatic vessels. After arrival at a distant organ, the 
mesenchymal phenotype facilitates extravasation and invasion into the foreign tissue. Here, disseminated 
cells are exposed to signals different from those of the primary tumor, and the mesenchymal state may confer 
survival advantages to single cancer cells or alternatively may support long-term dormancy. When the 
appropriate contextual signals become available, disseminated cells may undergo MET and gradually 
reacquire epithelial properties. Epithelial signals are reinforced through autocrine and paracrine signals. 
This facilitates the outgrowth of macrometastases that are composed predominantly of epithelial cells.  
Reprinted with permission from Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity 
in cancer. Nat. Med. Nature Publishing Group; 2013;19:1438–49, Copyright © 2013  
of MMPs in distal sites was postulated to prepare a niche, more compliant with the needs of 
the metastatic cancer cells. Additionally, osteolytic lesions in breast metastasis to bone often 
involve a crosstalk between cancer cells and cells involved in bone remodeling, such as 
osteoclasts.  
 Remodeling of Cell adhesion complexes 1.3.2.3
Additionally to matrix modulation, tumor cells rebuild their set of adhesion molecules to 
adapt to the specific microenvironment and to overcome barriers. Commonly observed is the 
downregulation of the epithelial adhesion marker E-Cadherin that is also part of the EMT 
program. Other specific examples of commonly dysregulated cell adhesion molecules are 
integrins [13,19]. Integrins were observed to form uncommon α- and β-complexes and enable 
interaction of the tumoral cell with ligands specifically expressed at distinct target sites. Both 
during dissemination of the primary tumor and the colonization of micro-metastases, the cells 
need to adapt to the local environment or to a local supportive stroma. Additionally, the 
rearrangement of adhesive complexes assists in the rearrangement of the cellular 
cytoskeleton, important for example for cell motility. 
Oncogenic mechanisms and inhibitors of TRAP 
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Figure 2 TRAP enzyme classification 
  Tartrate-resistant acid phosphatase/TRAP/ACP5 2
 Classification 2.1
Tartrate-resistant acid phosphatase (TRAP) is an enzyme belonging to the subclass of acid 
phosphatases (Figure 2), hydrolyzing phosphate ester bonds and anhydrides in the presence 
of water and acidic conditions into alcohols and phosphates [20]. Emerging as the 5th band 
separated by electrophoresis on an acidic native acrylamide gel and as the only acid 
phosphatase in serum insensitive to tartrate, it subsequently was designated TRAP/ACP5 
[21].  
Enzymes of this subclass are 
characterized by a binuclear iron 
center, rendering a purple color 
and thus the alternative name 
purple acid phosphatases (PAPs) 
[20]. Among the phosphatases, 
also other enzymes with two metal 
ions in their active site exist, e.g. 
the serine/threonine protein 
phosphatase 1 (PP1) and 2A (PP2A), combining them under the term binuclear (metallo-) 
phosphatases. Next to the resistance to tartrate and the purple color, PAPs can also be 
distinguished from other acid phosphatases by their molecular weights and a high isoelectric 
point (pI> 9) [20,22]. 
PAPs were isolated from microbes [23–25], plants [26,27] and animals [28–30]. PAPs found 
in plants are predominantly displaying molecular weights of 110 kDa with two homodimeric 
55 kDa subunits, whereas enzymes of the mammalian species are monomeric low molecular 
weights forms of around 35 kDa.   
Mammalian PAPs (bovine spleen and pig uterine fluid/´uteroferrin´) and TRAPs have been 
independently characterized for several decades, and therefore are referred to by multiple 
names. Only in the 1990s cDNA cloning, protein sequencing and immunological cross-
reactivity provided evidence that TRAP and PAP is actually the same enzyme [31–34]. 
 TRAP gene 2.2
 Chromosomal location and gene structure 2.2.1
The human TRAP gene has been mapped on a region on Chromosome 19p (19p13.2-13.3) 
[32,35], whereas the murine TRAP gene is located on chromosome 9 [36], rat TRAP gene on 
chromosome 8 [37] and pig TRAP gene (uteroferrin) on chromosome 2 [38], encoding one 
single gene. 
Mammalian TRAP genes have been cloned from mouse [36,39], human [32,39,40], rat [31] 
and pig [34]. The gene structure is overall highly conserved between species [34,41–43]; built 
up by 5 exons and the ATG-start-codon/translation initiation site at the beginning of exon 2, 
the promotor region is located on exon 1. Transcription gives rise to a ~1.5 kb mRNA with 
open reading frames of 975 bp in human macrophages [32] and 981 bp in the rat cDNA [31].  
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 Promotor regions 2.2.2
Studies of the 5´-flanking region in the murine gene suggest the presence of tissue-specific 
promotors resulting in three different mRNA transcripts, differing only in the non-coding 
exon 1 sequence [43,44]. The human gene displays a similar genomic structure, with four 
transcripts, differing in the exon 1 sequence [43]. Little sequence conservation was however 
noted upstream of the proximal promotor in the mouse and human gene [44]. 
 Transcriptional regulation 2.2.3
Within the human 5´-flanking region, several potential binding sites for transcription factors 
(e.g. PU.1, MITF) [20,45,46] have been identified, as well as two HRE (hemin response 
elements) motifs [47,48]. 
 TRAP protein 2.3
 Amino acid sequences  2.3.1
TRAP protein varies between 325, 327 and 340 amino acids when isolated and cloned from 
human macrophages, rat bone and pig uterus, respectively (Figure 3 A) [31,32,49]. In the rat 
protein a 21 amino acid signal sequence was identified resulting in a mature protein of 306 
amino acids [50]. A signal sequence of 19 amino acids was predicted in human macrophages 
by von Heijne´s rule [32]. Comparison of the amino acid sequences of isolations from 
different mammalian sources revealed a 81-94% of homology between species (Figure 3 B). 
It needs to be noted that amino acid numbering is derived from the mature sequences 
(21 amino acid signal peptide subtracted) and deviates between the TRAPs crystallized from 
different species due to differences in the in- or exclusion of two additional N-terminal 
residues of the rat/pig [51,52] and the human [53] crystal structures. 
 Crystal structures 2.3.1
Earlier, crystal structures have been derived for the 55 kDa dimeric plant enzyme from red 
kidney beans in a resolution of 2.9 Å (Protein data bank code KBP) [54,55], followed by 
crystallization of mammalian TRAP in a phosphate-enzyme complex (1.55 Å; 1UTE) [51]. 
Furthermore crystal structures were generated for the proteolytically cleaved (2.7 Å; 1QFC) 
and uncleaved (2.2 Å; 1QHW) forms of TRAP from rat bone [52,56]. Finally, crystal 
structures for the human TRAP with and without the repression loop (2.2 Å; 1WAR; Figure 
4 A) have been retained [53].  
Comparing all structures, conservation of a bisymmetrical organization with a βαβαβ-motif in 
each domain has been resolved, connected via a disulphide bond at residues Cys 142 and 
Cys 200 [52,56]. In this motif, the catalytic domains with the dimetal centers are located at 
the C-terminal ends and the metals ions are positioned in an octahedral geometry [53]. 
Binuclear iron centers in mammalian TRAPs are comprised by a chromophoric (Fe
3+
) and a 
divalent metal ion (Fe
2+
), which are redox active and display a pink color with absorption at 
λmax ~515 nm. Upon oxidation, the color shifts to purple (λmax  ~550 nm) and an inactive 
differric (Fe
3+
- Fe
3+
) enzyme [57,58].  
A flexible repression loop domain of 20 amino acids (1UTE, 1QHW, amino acid sequence 
145-164) (1WAR amino acid sequence 143-163) is located close to the active site in an 
exposed region [51,56]. 
Oncogenic mechanisms and inhibitors of TRAP 
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 Post-translational modifications 2.3.2
 Glycosylation 2.3.2.1
Mammalian TRAPs are glycoproteins containing up to two conserved surface exposed 
N-glycosylation motifs at Asn 97 and Asn 128 located in the N-terminal fragment of the two 
subunit form (represents Asn 95 and Asn 126 in human TRAP, Figure 4 A) [31]. 
Interestingly, these glycosylation sites were found to influence latency and catalytic 
properties of the recombinant monomeric TRAP, as mutations with a single oligosaccharide 
chain exhibited lower substrate affinity and catalytic activity [59]. Differences in molecular 
weights of the enzymes can be partially explained by differences in their glycosylation 
patterns. 
Figure 3 (A) Protein amino acid sequence alignment of pig TRAP, human TRAP, murine TRAP and rat TRAP 
5a, respectively * = amino acid identity; : = amino acid change in one sequence; . = amino acid change in 
more than one sequence. Loop area is marked in bold. Sequences were derived from NCBI or Uniprot and 
numbering includes a predicted signaling sequence of 21 amino acids marked with a vertical line, 
respectively. (B) Percent of identity of different mammalian TRAP structures. 
A 
B 
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 TRAP isoforms 2.3.2.2
TRAP exists as two isoforms, which was identified first due to a differential electrophoresis 
profile of serum samples [60]. TRAP is transcribed as a monomeric proenzyme and activated 
by posttranslational cleavage [30,61].  
The proteolytically cleaved two-subunit form TRAP 5b was isolated from rat and human 
bone [31,62], osteoclastomas [63] and human and bovine spleen [30,64]. After purification 
from bovine spleen homogenates, the single polypeptide as well as the heterogeneous 
subunits of the cleaved TRAP 5b form were compared [30]. Despite high homology in the 
protein, the monomeric proenzyme, also called TRAP 5a contains a flexible loop region, 
which is cleaved and released in the dimeric TRAP 5b isoform (Figure 4 A) [61]. Moreover, 
the TRAP 5a isoform displays several different biochemical characteristics compared to the 
TRAP 5b isoform. TRAP 5a contains sialic acid residues, which are not present in TRAP 5b 
[65,66]. The pH optimum for TRAP 5a is lower (pH ~5.2) than for TRAP 5b (pH ~5.8) as 
well as the specific activity of TRAP 5a, which is ~10X lower than that of TRAP 5b 
[60,65,67]. Substrate affinity is moreover lower in TRAP 5a, as Km values are increased, 
when compared to TRAP 5b [30,68]. 
A 
Figure 4 Recombinant human TRAP, (A) protein structure, resolution 2.2 Å, PDB ID 1WAR,  
(B) Active site, Graphics by Biognos AB, Martin Frank, 2015 
B 
Oncogenic mechanisms and inhibitors of TRAP 
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 Proteolytic cleavage 2.3.2.3
Orlando et al. were first in stating that cleavage of a five amino acid sequence in the loop 
region amino acid sequence 155-160 was suggested to be a process resulting in the two-
subunit structures, subsequently performed and proven by digestion with the serine 
proteinases trypsin and chymotrypsin [30]. Nevertheless, trypsin as a physiological enzyme 
processing TRAP in tissues and body fluids was regarded unlikely [69]. Later, several other 
cleavage enzymes, amongst them cysteine proteases and MMPs were tested in their capacity 
to cleave the proenzyme, as physiologically expressed in the osteoclast microenvironment 
[61,68]. Enzyme activity, sequence analysis, measurements of substrate specificity and site-
directed mutagenesis showed that cleavage with Cathepsin K and L, enzymes of the class of 
cysteine proteinases resulted in activation, comparable to the native bone enzyme. The amino 
acids Ser 145 and Asp 146 were pointed out to be important in the repressive function of the 
loop upon electrostatic interaction with amino acids Asn 91 and His 92 of the active site [69–
71].  
Altogether, proteolytical cleavage was proposed to function as a regulatory mechanism for 
the activation and degradation of the TRAP enzyme [61].  
 Enzymatic activity 2.3.3
 Active site structure and Catalytic reaction  2.3.3.1
In reviews from 2012 and 2013 about the mechanisms employed by TRAPs, the 
configuration of the active site and an step-wise model of the catalytic mechanism of TRAP 
were suggested [72,73]. 
In the active site, next to the conditional presence of water ligands, the ferric iron (Fe
3+
) is 
coordinated by a tyrosine (Tyr 55/Tyr 53), histidine (His 223/His 221) and an aspartate 
residue (Asp 14/Asp 12). The divalent metal iron (Fe
2+
) is coordinated by two histidine 
residues (His 221/His 219, His 186/His 184) and an asparagine (Asn 91/Asn 89). Aspartate 
(Asp 52/Asp 50) is bridging the iron ions [51–53,55] (Figure 4 B).  
(As previously noted, amino acid numbering in the respective studies deviates between the 
TRAPs crystallized from different species due to differences in the in- or exclusion of two 
additional N-terminal residues of the rat/pig [51,52] and the human [53] crystal structures.) 
Catalyzation of the hydrolysis of a monophosphate ester bonds was described as follows 
[72,73]: 
I Substrate binding to the enzyme in a second coordination sphere, formation of a pre-
catalytic complex 
II Substrate rearrangement, coordination to the divalent metal ion for the facilitation of a 
nucleophilic attack by µ-OH on the phosphorus atom of the substrate 
III Esterolysis of the substrate, free alcohol, phosphate remains bound 
IV Release of phosphate, regeneration of the resting state of the enzyme, reformation of 
the µ-OH bridge 
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 Redox activation 2.3.3.2
TRAP is activated generally by mild reducing agents such as β-mercaptoethanol, ascorbate, 
glutathione, dithiothreitol and Fe
2+
 converting the redox active Fe
3+
 ion to a Fe
2+
 concomitant 
with a color change from purple to pink [28,62,74,75]. A low concentration of ascorbate in 
combination with Fe
2+
 reduces the TRAP enzyme optimally and increases the catalytic rate 
[62]. Strong reducing agents bleach the TRAP enzyme upon removal of the ferric ions 
irreversibly [63]. Oxidizing agents only inactivate the enzyme via conversion of the Fe
2+ 
ion 
to a Fe
3+
, for instance by treatment with hydrogen peroxide [76]. 
 Substrates 2.3.3.3
In its reduced state, TRAP catalyzes the hydrolysis of various phosphate monoesters and 
anhydrides under acidic conditions [20]. In a study using recombinant and non-recombinant 
mammalian enzyme sources, TRAP exhibited high catalytic efficiency towards pyro-
phosphate and phosphotyrosine-containing peptides [77]. Phosphoserine and 
phosphothreonine-containing proteins, such as osteopontin and bone sialoprotein can 
moreover be dephosphorylated efficiently [78]. TRAP was suggested as an osteopontin 
phosphatase, given that it is colocalized with TRAP and that dephosphorylation of OPN has 
shown implications in adhesion and migration of osteoclasts and human choriocarcinoma cell 
lines [79–81]. Finally, dephosphorylation of focal adhesion kinase (FAK) 
autophosphorylation and global tyrosine dephosphorylation of FAK and Paxillin was shown 
in TRAP-overexpressing melanoma cells [82]. 
As TRAP has proven to exhibit relatively low substrate specificity, localization, activation by 
cleavage and a reducing and acidic environment of the enzyme can be suggested to stipulate 
the mechanism controlling its functional reach. 
 
 Cathepsin K/CtsK 3
 Classification and Enzymatic activation 3.1
Cathepsin K (CtsK) is a lysosomal enzyme with high homology in its primary sequence to 
members of the papain cysteine protease superfamily including cathepsins S, L, and B [83]. 
The CtsK gene is localized on chromosome 1q21 in humans [84] and on chromosome 3 in 
mouse [85]. CtsK protein is produced as a catalytically inactive pre-pro-enzyme, containing a 
signal sequence of 15 amino acids followed by a pro-leader sequence of 99 amino acids and a 
214 amino acid long catalytic domain [83]. The pro-enzyme displays a molecular weight of 
37 kDa and enzymatic activity is increased upon conversion to a 27 kDa mature enzyme. The 
pro-peptide in the pro-enzymatic form is required for correct folding of the catalytic domain, 
redirection to the lysosome and for maintaining the enzyme inactive [86,87]. CtsK is 
activated by either an autocatalytic mechanism [88] or in an acidic environment [83]. 
Nevertheless, activation of its collagenolytic and elastinolytic activity was also inducible at a 
physiological pH through allosteric modification by sulfated glycoaminoglycans [89].  
Oncogenic mechanisms and inhibitors of TRAP 
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 Pathological implications and Pharmacological targeting 3.2
CtsK degrades predominantly collagen type I, the major extracellular matrix protein of the 
bone, but was also shown to degrade other matrix proteins, such as osteonectin [83,90]. 
Initially, CtsK was assumed to have an exclusive role in bone resorption, as its abundant 
expression in comparison to other cysteine proteinases was specifically detected for 
osteoclasts (Figure 5) [91]. CtsK furthermore regulated the activation and intracellular 
localization of TRAP in osteoclasts [92] and colocalized with TRAP in resorptive 
compartments [68].  
CtsK has been studied regarding its role in a variety of pathological conditions related to 
bone, where CtsK levels were perturbed. In particular, lack of CstK function was associated 
to the bone related condition osteopetrosis [93,94] and the autosomal recessive gene disorder 
pycnodysostosis [95]. Contrary to that, increased CtsK activity, mRNA or protein levels were 
later also reported in a variety of primary tumors and CtsK found to be overexpressed in 
invading cancer cells at metastatic sites, such as the bone [96–99].  
With regard to its involvement in matrix degradation in bone, CtsK has served as a target for 
pharmacological inhibition in postmenopausal osteoporosis therapy, a condition of 
pathologically increased bone resorption [100,101]. Several attempts have been made to 
develop clinically tested anti-resorptive drugs by targeting CtsK, to retain osteoclast 
differentiation and bone formation [101–104]. Given that CtsK was also overexpressed in 
invasive cancer cells, the assumption has been made that CtsK implements a similar matrix 
degradation function also in the development of metastatic lesions. Hence, CtsK inhibitors 
were applied in mouse studies, where they effected a reduction in tumor burden and local 
metastasis, osteolytic lesions, as well as extracortial tumor growth [105,106]. Metastatic bone 
Figure 5 Bone-resorbing osteoclasts have multiple nuclei and a large number of vacuoles and lysosomes 
and form sealing zones. Vacuolar H+-ATPase localized in the ruffled border is involved in the transport of 
protons into the resorption lacunae, making it acidic. Enzymes such as cathepsin K, MMP9 and TRAP are 
secreted into the resorption lacuna to degrade bone matrix proteins. Matrix degradation products are 
endocytosed, packaged into transcytotic vesicles and secreted from the functional secretory domain. 
Osteoclasts express large numbers of receptors, which are e.g. involved in the cell–cell fusion of osteoclasts. 
Reprinted with permission from Takahashi N, Udagawa N, Suda T. Vitamin D endocrine system and 
osteoclasts. Bonekey Rep., Springer Nature; 2014;3., Copyright © 2013  
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disease was furthermore diminished in female patients with breast cancer, when the CtsK 
inhibitor Odanacatib was tested in a double-blind, randomized, controlled trial [107]. 
 TRAP and CtsK in bone remodeling. 3.3
Both TRAP and CtsK have been intensively studied regarding their involvement and 
processing in activated osteoclasts, resorbing bone. TRAP is, together with Cathepsin K, 
secreted during the bone-resorbing process into the sealed ruffled border area of the 
osteoclast and activated by conversion to TRAP 5b [68,92,108]. After degradation of the 
organic bone matrix by proteinases, TRAP 5b is, together with particles of the matrix, 
endocytosed by the osteoclast and transported in vesicles via the transcytotic route to the 
functional secretory domain for secretion into the extracellular space (Figure 5) [109]. 
 
 Osteopontin/OPN 4
 Structure and Regulation 4.1
Osteopontin is a secreted and intracellular protein of the class of small integrin-binding ligand 
N-linked glycoprotein (SIBLING) proteins. This family comprises five 
glycophosphoproteins, further including bone sialoprotein (BSP), dentin matrix protein 1 
(DMP1), dentin sialophosphoprotein (DSPP) and matrix extracellular phosphoglycoprotein 
(MEPE). OPN is further denoted as secreted phosphoprotein 1 (SPP1), early T-lymphocyte 
activation 1 (ETA1) protein or bone sialoprotein 1 (BSP1) [110].  
The structure of the OPN protein is defined by several highly conserved domains and 
functional motifs (Figure 6), such as the conserved arginine-glycine-aspartic acid- 
recognition (RGD) sequence, ELVTDFP and SVVYGLR sequences, a thrombin cleavage 
site and cleavage sites for MMPs, an aspartic acid rich sequence at its N-terminal, calcium 
binding sites and heparin binding domains at its C-terminal [111,112]. RGD, ELVTDFP and 
SVVYGLR motifs (available after cleavage with thrombin) enable binding and signaling via 
integrins [113]. An RGD-independent binding was shown for interaction with the CD44 
receptor [114] (chapter II.5).  
Regulation of OPN is highly complex, as the protein is subjected to extensive modification 
on the translational level and posttranslationally [115]. So far, three isoforms or splice 
variants have been identified, consisting of the full-length OPN-a, OPN-b lacking exon 5 and 
OPN-c lacking exon 4. Additionally, two further isoforms have been annotated. Isoform 4/d 
is lacking two alternate in-frame exons (missing protein sequence at location 95-116) and 
isoform 5 (missing protein sequence at location 59-72). Other splice variants have been 
mentioned, however, not yet been validated to a similar extent [116]. Additionally to the 
secreted version, alternative translation results in the generation of an intracellular form of 
OPN, a truncated version of the full-length protein lacking the signal sequence [117]. Further 
posttranslational modifications include e.g. cleavage, crosslinking mediated by 
transglutaminase, sialylation, phosphorylation, N- and O-glycosylation and sulfation, 
resulting in different functional forms (Figure 6) [118]. 
Oncogenic mechanisms and inhibitors of TRAP 
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 Functional implications of OPN 4.2
Osteopontin is expressed in a variety of cell types, such as bone and immune cells, epithelial, 
stromal and endothelial cells and was found in various tissues and secreted fluids [112]. 
It has been associated to a variety of functions and conditions related to bone remodeling and 
inflammatory responses. For a brief introduction, several review articles were selected, 
presenting OPN´s role in e.g. rheumatoid arthritis, systemic lupus erythematosus, 
osteoarthritis, inflammation in cancer and adipose tissue and bone homeostasis [112,119–
124]. During inflammation, OPN is triggering several immune cells to maintain the 
immunological response by inducing cytokine secretion [112]. On a cellular level, OPN was 
reported to be involved in osteoclast, macrophage and endothelial cell migration [80,125–
127], acting as coupling factor between cells and matrix. Based on the presence of 
crosslinking sites, it is also thought to be a stabilizing component of the bone matrix, 
produced by bone-building osteoblasts, as being able to crosslink to other components of the 
matrix, such as collagen type I [128].   
Osteopontin has moreover attracted interest as a marker of cancer development due to strong 
correlation with advanced stage in many cancer types. Several tumors types showed 
overexpression of OPN [110,129,130], whereas most cancers expressed hypophosphorylated 
OPN [131]. Numerous reviews furthermore elaborated in detail about the differential 
involvement of OPN as a tumoral and stromal protein in cancer [110–112,118,128,132,133]. 
The clinical relevance of OPN has been addressed e.g. suggesting it as a serum marker 
monitoring malignant pleural mesothelioma [134] and attributing it prognostic significance in 
Figure 6 Main domains of OPN. The cartoon depicts the functional parts of OPN. OPN binds two different 
classes of receptors, integrins (in blue) and CD44 (in pink). It can also interact with calcium (green). The 
SVVYGLR sequence is usually masked in the full-length molecule, but it becomes available upon thrombin 
cleavage of OPN. OPN undergoes several posttranslational modifications including glycosylation (red and 
green sugars), phosphorylation (yellow dots), crosslinking mediated by transglutaminase and protease 
cleavage (thrombin and MMPs). Each of these modifications can alter OPN functions.  
Modified with permission from Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, et al. 
Osteopontin at the Crossroads of Inflammation and Tumor Progression, Mediators Inflamm. Hindawi; Jul 9, 
2017 p. 1–22, Copyright © 2017 
 15 
II 
B
ack
g
ro
u
n
d
 –
 O
steo
p
o
n
tin
/O
P
N
 
limited-stage small cell lung cancer [135]. OPN has furthermore been reported to upregulate 
the expression of genes associated to EMT in aggressive breast cancer [136] and induced 
migration, invasion and EMT in endometrial carcinoma cells [137]. Splice variant OPN-c, the 
only variant that cannot form polymeric complexes, induced anchorage-independent growth 
in human breast cancer cells [138] and was repeatedly reported to be associated with cancer 
progression [116,139,140]. Further, OPN expression rescued MDA-MB-231 breast cancer 
cells from sensitivity to chemotherapeutic treatment and increased their proliferative potential 
[141]. OPN was also suggested to induce stem-cell like behavior in cancer cells [142,143]. 
Finally, cancer cells were shown to produce or stimulate stromal cells to produce osteoclast-
stimulating factors, such as OPN in the metastatic environment of the bone to enable niching 
and bone destruction [144]. 
 TRAP as an OPN phosphatase 4.3
TRAP was shown to be colocalized with the bone matrix protein osteopontin [145], and 
migration as well as adhesion of osteoclasts impaired upon dephosphorylation by TRAP 
[78,80]. Colocalization was further reported in macrophages and dendritic cells [146]. TRAP 
had the highest activity, when compared to bone alkaline phosphatase, as it was able to 
remove all phosphates of OPN [147]. This dephosphorylation further inhibited bone 
mineralization by OPN [147]. Low abundance of TRAP protein and activity caused by 
mutations in the ACP5 gene in patients with SPENCD increased ratios of phosphorylated 
OPN, resulting in an autoimmune phenotype [148]. Similarly, increased levels of 
phosphorylated OPN were detected in rheumatoid arthritis synovia, when TRAP activity 
ratios were decreased [149]. OPN was altogether suggested to be a major target of TRAP, 
affecting its functionality by dephosphorylation [81]. 
 
 Cluster of differentiation-44/CD44 5
 Structure and Splicing 5.1
CD44 is a transmembrane glycoprotein, encoded by a single highly conserved gene. 
Nevertheless, CD44 proteins are a group of extremely heterogenic molecules, derived from 
extensive alternative splicing and proteolytical processing [150]. Furthermore, CD44 is 
extensively modified by phosphorylations, glycosylation, palmitoylations, sulfation and 
attachment of glycosaminoglycans (GAGs). 
The CD44 gene contains 20 exons, whereas translation of exons 1-5 and 16-18 are constant in 
all isoforms, representing the standard isoform sCD44 [151]. Variant forms of CD44 
(vCD44) include exons that respectively elongate the extracellular variable isoform insertion 
site (Figure 7 A) [152,153]. Variable splicing of the v exons is observed in epithelial cells, 
endothelial cells, and inflammatory monocytes and commonly associated to aggressiveness 
and stem cell properties in tumors [153,154]. The simplistic structure of the transmembrane 
molecule is constituted by an (I) amino-terminal ectodomain, (II) a variable stem structure, 
(III) a transmembrane domain and (IV) an intracellular cytoplasmic tail (Figure 7 B) [151].  
Oncogenic mechanisms and inhibitors of TRAP 
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Whereas the amino-terminal domain serves as a docking site of extracellular matrix (ECM) 
components, such as hyaluronan (HA), osteopontin, collagen, laminin and fibronectin, the 
variable stem structure contains putative cleavage sites for MMPs and other sheddases, and is 
smallest in sCD44. The transmembrane domain is assumed to assist in the association with 
adaptor proteins and cofactors, whereas the cytoplasmic tail contains motifs for the anchoring 
of cellular skeleton proteins such as ERM (Ezrin, Radixin, Moesin) proteins and Merlin 
[150]. Upon proteolytical cleavage in both extracellular and intracellular domain the 
extracellular stem region of CD44 can be released as a soluble molecule whereas the 
intracellular domain can act as a nuclear signaling mediator [150,155].  
Figure 7 (A) Model structure of alternative splicing in CD44. CD44 pre-mRNA is encoded by 20 exons. 
CD44s form has a serine motif encoded in exon 5 that can initiate synthesis of a chondroitin sulfate or 
dermatan sulfate chain. Alternative splicing of CD44 predominantly involves variable insertion of 10 extra 
exons with combinations of exons 6–15 and spliced in v1–v10 into the stem region, of which v3 encodes a 
substitution site for a heparan sulfate chain. (B) Model structure of alternatively spliced CD44 proteins. 
CD44 is composed of an extracellular N-terminal domain, a stem region in the extracellular domain close 
to the transmembrane region, where the variant exon products (red/violet circles) are inserted, the 
transmembrane region, and the carboxyl terminal cytoplasmic tail. There are multiple sites for N-
glycosylation (purple circles) and O-glycosylation (orange circles), and a sulfation domain. The N-terminal 
portion contains highly conserved disulfide bonds as well as 2 BX7B motifs, both of which are essential for 
HA binding. The C-terminal cytoplasmic tail contains several phosphorylation sites that regulate the 
interaction of CD44 with the cytoskeletal linker proteins, as well as with SRC kinases  
Reprinted with permission from Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between 
hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front. 
Immunol. Frontiers; 2015, 17 Oct 2, p.201, Copyright: © 2015 
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 Receptor-ligand interactions and Signaling  5.2
CD44 can induce a variety of signaling cascades that can be clustered into several routes. 
CD44 can induce signaling (I) directly, (II) by acting as a coreceptor or (III) through 
accumulation and apposition of other proteins [152].  
Several ligands have been proposed to bind to the ectodomain of CD44, inducing signaling. 
Hyaluronan (HA) is a cell surface-associated glycosaminoglycan (GAG) and is the major and 
best-characterized ligand to CD44 [155].  It is synthesized and secreted by HA synthetases 
(HAS) and subjected to cleavage by hyaluronidases. It is also a major component of the 
ECM. Hyaluronan can bind both sCD44 and vCD44 isoforms and thereby activate the 
cytoskeleton or MMPs [155]. Binding to CD44 can results in uptake of hyaluronan to 
regulate its bioavailability [150] and high expression levels of both ligand and receptor were 
suggested as prognostic markers [156].  
Osteopontin is bound by both integrins and CD44 [114,127] (compare II.4). It was suggested 
that OPN/CD44 signaling is significantly involved in inflammatory processes and cell 
migration. 
Localization of proteolytically active membrane-degrading proteases, such as MMPs to the 
cell surface is important during invasion and metastasis and can be mediated by CD44. 
Matrix-bound MMPs are protected from inhibitors and can additionally act on CD44 by 
proteolytical release of domains to induce signaling [155]. For instance, TGFβ induced 
upregulation of membrane type 1-MMP and thereby released sCD44 via cleavage [157] 
Furthermore, colocalization of CD44 with the TGFβ receptor was shown to induce signaling 
and increase stability [158,159]. Moreover, complex formation with receptors of the Src-
family, Rho-family and the ErbB and c-Met receptor has been reported [151]. 
Intracellularly CD44 can interact with the cytoskeleton via e.g. ERM proteins [150].  CD44 
does not have an intrinsic kinase activity but induces signaling via accumulation of kinases 
and adaptor proteins. 
 Functional implications in cancer 5.3
CD44 has been suggested to be a cancer stem cell marker as it serves to integrate a wide 
variety of extracellular signals and signaling modes. It was shown to be functionally engaged 
in hematopoietic cell homing, matrix assembly, EMT and apoptosis and drug resistance in 
cancer cells [160]. It is also associated to cell migration and invasion, angiogenesis and 
suggested to function as a transcription factor [155]. Nevertheless, CD44 is implicated in 
functions inhibiting cancer progression [161]. This discrepancy is in part explained by the 
wide variability of CD44 proteins, the interaction factors and the stage of tumor progression, 
contribution to the complexity of CD44 involvement in cancer progression. 
Specifically, in hepatocellular carcinoma, sCD44 is upregulated, correlated to poor prognosis 
and reduced disease-free and overall survival. Similarly, it rendered valid as a upstream 
regulator of TGFβ-mediated EMT, as loss of sCD44 abrogated the TGFβ-mediated 
expression of vimentin, elongated morphology and tumor invasiveness [162]. 
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 Transforming growth factor β/TGFβ 6
 Activation 6.1
The TGFβ family is a group of proteins that are part of family of structurally related secreted 
cytokines [163–165]. TGFβ ligands exist in three isoforms, TGFβ1, TGFβ2 and TGFβ3 that 
are highly homologous. The most abundant form, TGFβ1, is a protein of 390 amino acids, 
while TGFβ2 and TGFβ3 contain 412 amino acids [166]. Commonly secreted is an form of 
TGFβ that is bound to the latency-associated protein (LAP) in an inactive complex. 
Association of latent TGFβ-binding proteins (LTBP) with the LAP/TGFβ complex assists in 
proper folding and secretion of the TGFβ precursor protein and regulates its bioavailability 
through binding to the extracellular matrix (ECM) [167]. The latent complexes are activated 
by proteolytical cleavage and traction forces through e.g. integrins, proteases, such as MMPs 
and thrombospondin-1 [168,169] (Figure 8).  
 Signaling 6.2
TGFβ proteins bind to transmembrane serine/threonine kinases, the TGFβ receptors (TβR). 
They are constituted of a class of seven type I (activing-receptor-like kinases/ ALKs) and five 
type II receptors. TβRII is a constitutively active receptor that can undergo 
autophosphorylation at Ser 213 and Ser 409, while Ser 416 phosphorylation has an inhibitory 
effect [170]. Ligand binding to TβRII allows for the formation of a hetero-oligomeric 
complex with a TβRI [168]. TβRII immediately transphosphorylates TβRI at its GS domain 
Figure 8 Stromal activators of TGF-β in the tumor microenvironment (A) MT1-MMP, MMP2 and 
MMP9, Plasmin, thrombin, BMP1 and fibulin-2 (B) MMP2, MMP3, MMP9 and MMP13 (C) Integrins 
αvβ (D) Reactive oxygen species/ROS and (E) Thrombospondin-1 (TSP-1). The mature (active) form of 
TGF-β can then bind to its cognate receptor and exert its tumor promoting and tumor suppressive 
properties. Dashed arrow indicates recruitment of the mature TGF-β protein to its cognate receptor. 
Reprinted with permission from Costanza B, Umelo I, Bellier J, Castronovo V, Turtoi A. Stromal 
Modulators of TGF-β in Cancer. J. Clin. Med.. Multidisciplinary Digital Publishing Institute; 2017;6:7. 
Copyright ©2017 
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(TTSGSGSG). Mutations in this motif can either lead to an impairment of the kinase activity 
or results in a partial activation [170]. Phosphorylation of TβRI then leads to the recruitment 
and phosphorylation of intracellular effector proteins, ultimately leading to the transcription 
of various target genes.  
Intracellular signaling mediated through TβRI/II is regulated either via the canonical mothers 
against decapentaplegic (SMAD)- (Figure 9 A) or non-SMAD-mediated pathways (Figure 
9 B) [165,170–173]. SMAD proteins are categorized in three classes: receptor-regulated 
SMADs (SMAD-1, -2, -3, -5, -8), a common mediator SMAD-4 and inhibitory SMAD-6 and 
SMAD-7 [166]. Upon phosphorylation by TβRI, SMAD-2- and SMAD-3 associate with 
SMAD-4 and mediate nuclear translocation. Non-SMAD-mediated pathways include the 
activation of mitogen-activating protein kinase (MAPK), TRAF6, TAK1, 
phosphatidylinositol-3 kinase (PI3K) and small GTPases such as Rho [166,174–179]. 
Interestingly, TGFβ signaling was coupled to transactivation and interaction with other 
signaling receptors and pathways, such as CD44 or integrins.  
Figure 9 TGF-β signaling pathway (A) TGF-β ligands signal through distinct receptors and SMADs that 
are modulated by adaptor proteins, such as β2-spectrin (β2SP), and ubiquitinators. At all levels, SMAD 
modulation occurs through adaptor proteins as well as E3 ligases such as PRAJA and Smurfs, generating 
diverse and complex signals. (B) SMAD-independent signaling, including mitogen activated protein kinases 
(MAPKs), phosphoinositide 3′ kinase (PI3K), TRAF6-TAK1-p38/JNK, Rho-Rock, among others. Such 
alternative signal transducers often regulate the SMAD pathway. TF: transcription factor 
Reprinted with permission from Katz LH, Li Y, Chen J-S, Muñoz NM, Majumdar A, Chen J, et al. Targeting 
TGF-β signaling in cancer. Expert Opin. Ther. Targets. Taylor & Francis; 2013;17:743–60. 
Copyright ©2013 
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Figure 10 In normal and premalignant cells, TGFβ enforces homeostasis and suppresses tumor 
progression directly through cell-autonomous tumor-suppressive effects (cytostasis, differentiation, 
apoptosis) or indirectly through effects on the stroma (suppression of inflammation and stroma-derived 
mitogens). However, when cancer cells lose TGFβ tumor-suppressive responses, they can use TGFβ to their 
advantage to initiate immune evasion, growth factor production, differentiation into an invasive phenotype, 
and metastatic dissemination or to establish and expand metastatic colonies.  
Reprinted with permission from Massagué J. TGFβ in Cancer. Cell. Cell Press; 2008, p. 215–30. 
Copyright  ©2008 
For instance, TβRI was shown to contain a single cytoplasmic binding site for CD44 and 
binding of hyaluronan to CD44 stimulated the kinase activity of TβRI, which in turn 
increased SMAD-2/3 phosphorylation in metastatic breast cancer cells [158]. TGFβ1 
moreover upregulated hyaluronan synthases (HAS) and promoted the expression of CD44 
during EMT induction through HA/CD44 [180]. On the contrary, microarray analysis 
identified TGFβ2 as a downstream transcriptional target of CD44 signaling in the presence of 
hyaluronan in breast cancer cells [181] Furthermore, TNFα stimulated the formation of the 
HA/CD44/moesin complex, which lead to an interaction and activation of SMAD-dependent 
TβR signaling, resulting in ECM production and cell motility in a fibrosis model [182]. 
Contradictory to that, CD44 stabilized and thereby inhibited TβRI signaling in normal dermal 
fibroblasts [159]. Finally, integrin signaling was shown to potentiate TGFβ-dependent effects 
on EMT [183]. 
 TGFβ in tumor suppression and progression 6.3
TGFβ proteins and signaling is an immensely studied field. Searching for publications in 
2017 in the field of cancer involving either transforming growth factor or TGF in the title 
delivers hundreds of reports.  
Generally, TGFβ acts as a pleiotropic cytokine, though, has a bidirectional role during cancer 
progression. In early stages and normal tissues TGFβ represses tumorigenesis, whereas it acts 
as an oncogene in late stages [164]. A plethora of effects and observations has been made and 
attributed to the TGFβ proteins and signaling in the regulation of cancer development 
(Figure 10). 
 
 Increased TGFβ expression in tumor 
cells correlating with disease 
progression, tumor stage or survival  
[184–187] 
 Development of treatment resistance 
[188,189] 
 Angiogenesis [190–193] 
 Immunosuppression [194–197] 
 Master regulator of EMT [198–201] 
 Autocrine regulation of its own 
signaling [202]  
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 TRIP-1, a bridge between TGFβ and TRAP 6.4
TβR-interacting protein-1 (TRIP-1) is an intracellular protein identified as a phosphorylation 
target of the TβRII kinase and as a functional component of eukaryotic translation initiator 
factor 3 (eiF3) multiprotein complex [203]. TRIP-1 was shown to negatively modulate 
TGFβ-dependent functions, such as the induction of EMT and plasminogen activator 
inhibitor-1 expression [203,204]. Secreted into the ECM via exosomes, it was shown to 
increase matrix mineralization in bone upon binding to collagen type I [205]. 
TRAP was shown to interact intracellularly with TRIP-1 thereby activating TβRII and 
osteoblast differentiation through the SMAD-2/3 pathway at sites of prior bone resorption 
[24]. Furthermore, TRIP-1 knockdown abrogated osteoblast differentiation and proliferation 
[25]. Finally, TRAP 5a interaction with TRIP-1 has been demonstrated in mouse pre-
adipocytes [26]. 
 
 Physiological and pathological implications of TRAP  7
 Cell and tissue expression  7.1
Upon search in the human protein atlas database, expression of RNA and protein is mainly 
found in bone marrow and the immune system, the lung and the kidney and urinary bladder 
(https://www.proteinatlas.org/ENSG00000102575-ACP5/tissue) [206]. TRAP mRNA 
expression has been found in e.g. the thymus, liver, small intestine, lymph nodes and the bone 
marrow [207]. Human epithelial cell expression has been detected in a variety of tissues, such 
as e.g. spleen, skin, lung, colon and ileum [207]. Apart from that expression was found in 
tissue-specific macrophages such as in adipose tissue [208], in the liver [209] and in the lung 
[210]. TRAP was also expressed during maturation of dendritic cells [207] and in bone-
resorbing osteoclasts [211]. Moreover, TRAP expression was found in the nervous system of 
rats [212]. A detailed look into isoform selectivity in rat tissues revealed that monocytes in 
the spleen, thymus, liver and colon were majorly positive for TRAP 5b, whereas epithelial 
cells in colon, lung and kidney were positive for the monomeric TRAP 5a variant [213]. 
 TRAP isoform processing, Intracellular localization and Secretion 7.2
In a mammalian cell line stably overexpressing TRAP, monomeric TRAP 5a is a precursor, 
distinctly separated early in the endoplasmatic reticulum of cells to either provide a pool for 
secretion or to be subjected to proteolytic processing for generation of the intracellular 
isoform TRAP 5b [214]. Concomitant with that, in macrophages and dendritic cells TRAP 5a 
gets secreted, whereas TRAP 5b retains intracellularly [66,215]. In osteoclasts, monomeric 
TRAP 5a is secreted via the secretory pathway and the ruffled border area into the resorption 
lacunas and gets cleaved extracellularly by cysteine proteases [68] (Figure 11). As TRAP is a 
lysosomal enzyme, supplied with a mannose-6-phosphate lysosomal targeting sequence, it 
was assumed that this sequence must presumably be cleaved or modified for TRAP to be 
secreted [20]. 
Oncogenic mechanisms and inhibitors of TRAP 
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 Proposed functions 7.3
A particular function for TRAP has so far not been identified, nevertheless, TRAP was 
associated to a series of processes, both involved in physiological and pathological 
conditions:  
Phosphorylation-independent: 
 Generation of reactive oxygen species [216–219] 
 Iron transport [220–222] 
 Growth and differentiation factor [223–226] 
 Regulation of immune responses [146,148,217,227] 
Phosphorylation-dependent: 
 Marker of osteoclast activity and bone resorption [211,228,229] 
 Regulation of osteopontin phosphorylation and bioactivity [81,146] 
 Osteoclast and epithelial cell migration [80,230] 
 Provinvasion driver in cancer cells [82] 
 Transport of lysosomal proteins [231,232] 
Figure 11 TRAP isoform location and processing in TRAP-overexpressing cancer cells, macrophages 
and osteoclast 
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 TRAP pathology 7.4
 Conditions associated to bone metabolism 7.4.1
TRAP 5b is highly expressed in osteoclasts and a marker of osteoclast activity [229]. 
Elevated levels of TRAP have been reported in Paget´s disease, a chronic disorder associated 
with disorganized bone remodeling [233]. A uncoupling of bone formation and resorption is 
present in osteoporosis and elevated serum levels of TRAP were found in postmenopausal 
women with osteoporosis [234]. In osteolytic lesions of multiple myeloma, levels of TRAP 
5b were furthermore found to be increased [235]. 
Additionally, mice lacking TRAP expression displayed disrupted endochondral ossification 
and mild osteopetrosis [228], whereas TRAP overexpression led to an increased bone 
turnover [236].  
 Macrophages and Inflammatory diseases 7.4.2
Macrophages extensively expressed TRAP compared to their monocytic precursors [32] and 
in an activated or inflammatory state [237]. TRAP expression in macrophages was associated 
with an enhanced capacity of bacterial killing [216,238]. Restricted expression of TRAP 5a in 
inflammatory macrophages lead to the suggestion of TRAP as a marker of chronic 
inflammation [237].  TRAP protein levels were increased, however, specific TRAP activity 
was decreased in rheumatoid arthritis, suggesting the involvement of TRAP 5a derived from 
inflammatory macrophages [239]. Next to rheumatoid arthritis, TRAP was also detected in 
other autoimmune diseases like e.g. the lysosomal storage disease Gaucher´s disease 
[21,60,240]. Recently, in mouse models and patients diseased with chronic obstructive 
pulmonary disease (COPD) and asthma, higher expression and activity of TRAP was found, 
associated to expression in alveolar macrophages [241]. 
TRAP 5a overexpression was furthermore associated with hyperplastic obesity in mice and 
induced proliferation and differentiation of adipocyte precursor cells [242]. This could be 
possibly explained by findings on a molecular level that showed TRAP 5a binding to the 
membrane of pre-adipocyte mediating a colocalization with glycosaminoglycans (GAGs) and 
subsequent calveolae-mediated endocytosis [224]. TRAP secreted by macrophages in the 
subcutaneous adipose tissue suggested involvement of TRAP in lipid accumulation and 
adipose tissue inflammation [208]. 
 Spondyloenchondrodysplasia (SPENCD)  7.4.3
SPENCD is regarded primarily as a skeletal disorder, recently associated with biallelic 
mutations in the human TRAP gene leading to a loss of protein or enzyme activity [148,243]. 
Additionally to the characteristic metaphyseal and vertebral bone lesions, patients displayed a 
variety of autoimmune phenotypes linked to the accumulation of phosphorylated osteopontin 
(OPN) in serum, urine and cells. Deregulation of OPN bioactivities as a result of impaired 
dephosphorylation by TRAP was connected to the activation of dendritic cells and an 
enhanced inflammatory cytokine signature [148]. Disturbed processing concomitant with 
accumulation of phosphorylated OPN was moreover detected in TRAP-deficient mice [244]. 
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 Cancer and Metastasis 7.4.4
 Histochemical marker 7.4.4.1
Initially, among blood-derived cells, only reticuloendothelial cells of leukemic reticulo-
endotheliosis (hairy cell leukemia) showed exclusive expression of acid phosphatase band 5, 
i.e. TRAP [240]. Soon after, restrictive expression of TRAP in hairy cell leukemia cells and 
absence in other hematopoietic cells was proven [245], suggesting the usefulness of TRAP as 
a marker enzyme for the detection of hairy cell leukemia. Later, TRAP could be isolated from 
spleen [64] and was identified by means of immunohistochemistry in lymphoid cells in the 
bone marrow [246] in cases of hairy cell leukemia. Nowadays, histological TRAP staining 
has been routinely used in diagnostics for hairy cell leukemia for more than four decades. 
 Serological marker in bone metastases 7.4.4.2
Bone metastases typically derive from several types of cancer increasing morbidity and 
prognosis, breast and prostate cancer representing about 80% thereof [247]. Clinical 
applicability of serum TRAP isoform 5b was widely suggested for the diagnosis of metabolic 
and pathological bone diseases, reflecting the extent of lytic bone metastasis and tumor 
burden. The development of specific TRAP 5b immunoassays highly promoted diagnosis of 
bone metastasis [248]. Specifically, TRAP 5b has been proposed as a serum marker in several 
studies addressing bone metastases in breast cancer [248–252], prostate cancer [253–255], 
multiple myeloma [235] and non-small cell lung cancer [256]. 
 Cancer-associated inflammation and Cachexia 7.4.4.3
Macrophage expression of TRAP detected by immunohistochemistry in colon cancer was 
associated with improved outcome, increasing the 5-year survival rate and a risk-reduction in 
disease specific death [257]. Only specific macrophages were positive, when anti-CD68 
staining was applied, however, expression could not be restricted to the M1/M2- 
classification. 
Very recently, TRAP 5a was rendered a role as a chronic inflammatory marker and a possible 
prognostic marker for cancer cachexia in different types of cancer [258]. TRAP 5a activity to 
protein levels were elevated in cancer patients suffering from cachexia with its serum activity 
significantly correlated to a decreased patient survival. 
 Cancer cell expression and Clinical relevance 7.4.4.4
Several studies of the last decade found TRAP expression in cancer cells, redirecting the 
general assumption that serum levels of TRAP in cancer patients with bone metastases would 
primarily derive from an increase in osteoclastic resorption or macrophage expression. 
In a study from 2006 assessing serum levels of cancer patients, Honig et al. [259] detected 
TRAP expression in breast patients regardless of the presence of bone metastases. To pursue 
in this direction, several cancer cell lines, primary cancer cells as well as cancer tissues were 
analyzed for TRAP mRNA and protein levels. Expression was found in breast, ovarian, 
cervical cancer and malignant melanoma, whereas benign sites were either low in or absent 
of TRAP protein [259]. Moreover, expression of TRAP was detected in cells cultured from 
pleural effusions and malignant ascites [259]. In parallel, TRAP activity and protein was 
identified in several commercially available breast cancer cell lines. In another study, protein 
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expression, evaluated by immunohistochemistry, was increased in human breast tumors with 
advancing malignancy [260].  
Apart from expression, TRAP was also associated to clinically relevant parameters of cancer 
progression in patients and was assessed for its oncogenic potential in mouse models.  
TRAP was initially identified as one of six proinvasion oncogenes during a genetic screen for 
invasion and metastasis drivers in melanoma [82]. As a functional and clinical validation to 
this finding, Scott et al. showed that TRAP (I) induced tumorigenicity and metastasis 
development in various mouse models (II) expression was increased when comparing benign 
to malignant and primary to metastatic tumors (III) reduced tumor- and metastasis-free 
survival in melanoma significantly. In hepatocellular carcinoma, increased expression of 
TRAP was found in tumor tissues when compared to adjacent tissue [261]. TRAP 
furthermore correlated to microvascular invasion, poor differentiation and higher tumor– 
node–metastasis (TNM) stage. It decreased overall survival and increased the incidence of 
metastasis in both patients and mouse models and served as a risk factor for disease 
recurrence [261]. Later on, in gastric cancer, TRAP was attributed a clinically relevant 
function as an independent risk factor for peritoneal dissemination and was associated with 
lymph node metastasis and  shorter survival [262]. Expression was again shown to be 
significantly higher in cancer tissues than adjacent normal mucosa. TRAP was moreover 
upregulated in lung adenocarcinoma and high expression significantly related to lymph node 
status, TNM stage, and differentiation [263]. High TRAP expression served as an 
independent prognostic factor for overall survival.  
Altogether, these studies support the clinical relevance of TRAP during cancer development 
and progression. They furthermore prove that tumor-derived TRAP is a relevant source 
contributing to elevated enzyme activity in serum. 
 TRAP isoforms in cancer  7.4.4.5
In cancer specimens, metastatic samples from patients with different kind of primary tumors, 
e.g. prostate, breast, lung and kidney displayed expression of both TRAP 5a and TRAP 5b 
isoforms. Interestingly, a novel TRAP 5a 42 kDa isoform restricted to metastatic cancer 
tissue was indicated. Monomeric isoform 5a was predominantly expressed by metastatic 
cancer cells, whereas the cleaved isoform TRAP 5b was expressed in tumor-associated 
macrophages and multinucleated giant cells in the tumor stroma [264]. 
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 TRAP inhibitors 8
Similarly to other phosphatases, TRAP can be inhibited by fluoride and tetrahedral 
oxyanions such as molybdate, tungstate, arsenate, vanadate and phosphate by binding into the 
active site [55,58,62,265–267]. However, such compounds are ineffective as selective 
inhibitors, often weak, toxic and lacking drug-like characteristics. In addition, they commonly 
affect other phosphatases as well. 
Several attempts have been made to identify more selective and potent substances to inhibit 
the TRAP enzyme: 
 Phytochemicals 8.1
In an attempt to find anti-osteoporosis phytochemicals, terpenes and sterols from the fruits of 
Prunus mume were isolated and their effects on TRAP activity and osteoclast differentiation 
was investigated [268]. Nevertheless, none of the substances was able to minimize TRAP 
activity more than by 50%. Furthermore, flavonoids, such as phytoestrogens have been 
shown to reduce osteoclast precursor differentiation via acting on Receptor Activator 
of NFκB Ligand (RANKL), a stimulator of TRAP expression [269]. Following, these results 
were continued showing a reduction of TRAP activity in osteoclast-conditioned medium 
obtained by treatment with selected flavonoids, concordantly with a reduction in pit 
formation [270].  
 Substrate mimics 8.2
Several efforts have been funneled also into the design and optimization of substrate mimics 
of TRAP. TRAP was shown to dephosphorylate phosphotyrosine and related peptides 
[77,271]. Substrate derivates were built based on modifications and structural optimizations 
of the latter peptides and replacement with more stable phosphotyrosyl analogues. The 
selected peptides displayed inhibitory constants in the µM range and docked into the active 
site [272]. Additionally, bone pit formation activity of osteoclasts was inhibited when treated 
with inorganic polyphosphates, associated with a potent inhibition of TRAP activity [273]. 
Here, the longer phosphate side chains affected the inhibition potency positively, without 
introducing any changes in cell number or differentiation. 
 Gold coordination compounds  8.3
Gold compounds have been applied in the past to treat medical conditions with inflammatory 
reactions, such as rheumatoid arthritis. Given that the reactive mechanism has never been 
understood and several side effects were observed, its application was discontinued in the 
clinics. Nevertheless, gold compounds rendered valuable as inhibitors of TRAP. Gold-
chloride was reported as a potent non-competitive inhibitor by inhibiting the phosphorylation 
of OPN [274]. In contrary, the gold compounds aurothiogluccose and aurothiomalate proved 
ineffective on TRAP activity [274]. Additionally to this study, we recently showed 
applicability of the gold coordination compound AubipyOMe on TRAP activity, as it was 
able to inhibit TRAP activity in macrophage lysates and lung tissue extracts. Furthermore the 
gold compound inhibited migration in macrophages stimulated to express TRAP by RANKL, 
without affecting unstimulated macrophages [241]. 
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 Rational drug design: phosphonic acids 8.4
Based on the scaffold of 1-naphtylmethyl phosphonic acids, synthesized as inhibitors of 
TRAP [275], more compounds were designed by computational modelling and rational drug 
design in follow-up studies [276,277]. This approach of finding inhibitory compounds is 
based on the strategy to predict appropriate derivatives of lead compounds followed by 
empirical testing and evaluation for bioactivity. Several derivates were chemically produced 
with respect to their anticipated binding pattern, leading into a family of α-alkoxy-
naphtylmethyl phosphonic acids tested to be active in the pig and plant TRAP enzyme [276]. 
A second generation of this family, i.a. acyl derivates, furthermore proved valid as active 
inhibitors of TRAP, dependent on the acyl chain length, as predicted by high docking scores 
[277]. Here, α-alkoxy-naphthylmethyl phosphonic acids, predicted to display the highest 
binging affinities also rendered most potent, when tested on the recombinant enzymes. 
 Fragment-based screening: lead structures  8.5
Fragment-based screening was further applied in a study from Feder et al. [278], with the aim 
of finding lead structures from a library with drug-like characteristics that bind into the active 
site of TRAP. Screening approaches are a second approach commonly applied to identify 
potential small molecule inhibitors that enable structural optimization by modulations based 
on the leads structures. Three fragments were found, amongst them 5-phenylnicotinic acid 
(5-PNA), inhibiting the TRAP enzyme in the µM range and displaying favorable parameters 
and high ligand binding efficiencies applying crystallography and assessing docking modes. 
Despite similarities of the applied plant enzyme to the human enzyme, none of the lead 
structures were assessed for their functionality on the human TRAP or in their applicability in 
a cell based system. 
Oncogenic mechanisms and inhibitors of TRAP 
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III PRESENT INVESTIGATION 
 
 
 Aims of the thesis 1
 
Overarching aim: 
 
These studies addressing the role of TRAP enzyme in the development of cancer were 
founded on two major milestones. We aimed (I) to identify and/or characterize novel and 
potent small molecule compounds inhibiting the activity of TRAP and (II) to dissect 
molecular mechanisms of TRAP action in cancer cells overexpressing TRAP. 
  
Specific aims: 
 
 To further characterize the inhibition potency and applicability of the small molecule 
inhibitor 5-PNA on the two TRAP isoforms and to test its functionality on the 
mammalian enzyme and in a cancer cell system 
 To screen for potent small molecule inhibitors applicable to either or both TRAP 
isoform  
 To specify functional effects of TRAP overexpression at a cellular level 
 To outline signaling and network perturbations upon modulation of TRAP expression 
 To identify possible TRAP substrates 
 To evaluate the involvement of Cathepsin K in the generation of TRAP isoform 5b 
 To dissect the role of TRAP isoforms 5a and 5b during cellular transformation  
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 Considerations on the Methodology 2
 Ethical considerations 2.1
In all studies included in this thesis, recombinant proteins or commercially available cell lines 
were applied. No animal studies or patient material was used. Therefore, ethical approval was 
not necessary and general guidelines for research ethics consulted. 
 Small molecules and Blocking antibodies 2.2
In the course of inhibition experiments and for delineation of the relative involvement of 
candidate molecules, small molecule inhibitors and blocking antibodies were applied. In 
control conditions, respective concentrations of DMSO solvent or IgG antibodies were 
applied. 
 Small molecule libraries 2.2.1
To screen for TRAP inhibitors we made use of a highly specialized and characterized library 
of small molecule compounds supplied by the Chemical Biology Consortium Sweden 
(CBCS, www.cbcs.se). This library is originally derived from the pharmaceutical industry 
(Biovitrum AB) and is consistently updated, expanded and filtered for small molecules free 
from unwanted characteristics such as promiscuity, compound interferences, aggregators, 
PAINS and REOS. All compounds display drug-like characteristics with respect to molecular 
weight, hydrogen bond accepting and donating groups, lipophilicity and polar surface area. 
For Paper II, we applied a primary screening set, consisting of both proprietary and 
commercially available compounds with chemical diversity. Original compound batches 
were stored in concentrations of 10 mM in DMSO and consistently tested for identity and 
purity. Compounds were further handled by subsequent dispensing. 
 TRAP-inhibitor 5-PNA 2.2.1
The small molecule inhibitor 5-phenylnicotinic acid (5-PNA/CD13) is a chemical compound 
of 200 Da and was initially found to be a TRAP inhibitor for red kidney bean TRAP with 
drug-like properties within an approach using fragment-based screening [278]. This inhibitor 
was shown to block TRAP activity of the plant and pig enzyme at Kic values around ~40 µM. 
5-PNA co-crystallized into the active site of the plant TRAP enzyme upon interaction with 
the iron residues assessed by X-ray structures and molecular modelling. In Paper I, we 
further characterized the applicability of 5-PNA and then used it as a specific inhibitor to 
target TRAP function in Paper III. Considerations regarding the use of 5-PNA have been 
addressed in the results and discussion of Paper I (chapter III. 3.1.1 and 3.1.2).  
 Inhibitors and Blocking antibodies for TβR, TGFβ2 and CD44  2.2.2
To target the involvement of selected candidates in Paper III, small molecules and blocking 
antibodies to inhibit respective effects of TβR, TGFβ2 and CD44 were applied. To target 
TβR, LY2109761 (Santa Cruz, CAS 700874-71-1, PUBCHEM CID 11655119) a 
selective dual inhibitor of TGF-β receptor type I/II (TβR I/II) activity was administered, 
proven to negatively affect the phosphorylation of SMAD-2. To normalize levels of TGFβ2, 
the blocking antibody AB-12-NA (R&D systems) was applied. Similarly, a CD44-blocking 
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antibody (Hermes-1, NBP2-22530, Novus Biologicals) was used to assess the relative effect 
of CD44. Antibodies detecting the phosphorylation sites, Ser 179, Ser 180 and Ser 183 in the 
intracellular portion of the CD44 receptor were not available. 
 Cathepsin K inhibitors 2.2.3
The highly potent and irreversible cysteine proteinase inhibitor E-64 has been used in earlier 
studies to dissect CtsK involvement, e.g. in the activation of TRAP in osteoclasts and cancer 
cells [92,214]. E-64 is a pan-cysteine proteinase inhibitor, as targeting also e.g. Papain, 
Cathepsin L and Cathepsin B [279]. Despite not being an optimal candidate for the use as a 
drug, E-64 is widely applied as a research tool for the characterization of cathepsins and to 
clock proteinase activity. 
In Paper IV, we applied the small molecule Cathepsin K inhibitor Odanacatib (MK0822, 
Selleckem). Odanacatib was developed based on a structural modification of a previously 
tested compound and has rendered to be similarly effective but more selective against other 
Cathepsins [100,280,281]. Odanacatib is a reversible active site inhibitor [280] and 
discontinuation of treatment restored osteoclastic bone resorption and CtsK secretion [282]. 
Several attempts have made to assess the relevance of blocking Cathepsin K in diseases with 
high Cathepsin K levels and activity such as postmenopausal osteoporosis [100] and breast 
cancer with bone metastases [105–107]. Despite reduction of CtsK-associated bone fractures, 
the clinical phase III study with Odanacatib [283] was discontinued, as recurrent side effects, 
i.e. increased risk for stroke were observed.  
 Enzyme preparations 2.3
TRAP enzyme was purified from various sources, cleaved and applied in Paper I, II and IV.  
 Monomeric TRAP 5a purification 2.3.1
Recombinant human or rat TRAP was derived from conditioned medium from Baculovirus-
infected Spodoptera frugiperda (Sf9) insect cell culture (obtained from GenScript USA. Inc.), 
concentrated, complemented with protease inhibitors and removed from any cell debris. 
Similarly, TRAP was extracted from conditioned medium of TRAP-overexpressing cancer 
cells. TRAP was purified by column separation within an ÄKTA purifier
TM 
10 FPLC
 
system 
according to a protocol derived from several publications [214,266,284], described in detail 
in the Material and methods section of Paper I. Briefly, supernatants were loaded onto 
Sulphopropyl-Sepharose HiPrep SP FF16/10 columns and eluted on a linear gradient from 
0.1 M to 0.5 M NaOAc, pH 6.5. Protein containing fractions were further applied onto a 
HiPrep Phenyl FF 16/10 column and TRAP eluted on a linear gradient from 50 mM NaOAc 
and 1.1 M ammonium sulphate towards 50 mM NaOAc,  pH 5.0. The pooled fractions were 
then dialyzed against a buffer containing 0.1 M NaCL, 0.005% Triton X-100, 20 mM Tris-
HCl pH 7.2 and loaded on a HiTRAP Heparin HP column followed by an additional elution 
on a linear gradient from 0.1 M NaCl towards 1 M NaCL. Fractions were pooled and frozen 
at -80 °C and used within a limited number or freeze-thaw cycles to inhibit spontaneous 
cleavage.  
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 Generation of TRAP 5b by proteolytic cleavage 2.3.2
To obtain recombinant TRAP 5b, TRAP 5a purifications were incubated with human liver 
Cathepsin L for 2-3 h a 37 °C. The reactions were stopped on ice and by addition of protease 
inhibitors, such as cysteine proteinase inhibitor E-64. Complete cleavage was confirmed by 
Western Blotting and activity measurements. Aliquots were frozen and used within a limited 
number of freeze-thaw cycles to inhibit degradation and activity loss. 
 Purification of native cleaved TRAP 5b 2.3.3
Native TRAP 5b derived from bone tissue were used from previous isolations [266,285]. A 
comparison of the TRAP derived from bone with its recombinant counterpart, extracted from 
Sf9 cells was documented in a study from Ek-Rylander et al. [266]. 
 Cell lines 2.4
Adams et al. [260] previously reported expression and activity of TRAP in human cancer cell 
lines and tissues. In their study three breast cancer cell lines (MCF-7, T47-D, MDA-MB-435) 
and mammary luminal epithelial cells Hb4a displayed TRAP enzyme activity and MDA-MB-
435, the most tumorigenic of these line, has two-fold higher TRAP activity than the other cell 
lines. In a study from Honig et al. [259] MDA-MB-468, MCF-7, BT20 and HBL-100 breast 
cancer cell lines expressed TRAP. Increased TRAP expression was additionally assessed in 
1205Lu and M619 melanoma cell lines [82] and SMMC7721 hepatocellular cell lines [261]. 
The invasive breast cancer cell line MDA-MB-231 was used in Paper I-IV as a model system 
to characterize the impact of levels of TRAP expression on several parameters in breast 
cancer cells. As this cell line expresses low levels of endogenous TRAP, it was surmised that 
cellular processing of TRAP was highly similar to the one in cells with high expression. Low 
expression levels assured that TRAP expression would only derive from the overexpression 
vector. This cell line has not been applied to studies assessing the effect of TRAP on cancer 
progression, and its use further provided a model to assess the effect of TRAP in late tumor 
progression.  
 TRAP-overexpressing MDA-MB-231 breast cancer cells 2.4.1
The TRAP-overexpressing cell line was previously generated by stable transfection with a 
plasmid containing the full rat sequence [214]. TRAP derived from different mammalian 
sources reveals high homology in amino acid sequences (Figure 3B) and identical 
biochemical properties [31,32,49,286]. Effects induced by overexpression of the rat sequence 
are thus comparable to a human TRAP overexpression. Zenger et al. [214] previously 
characterized the cell population overexpressing TRAP and described the biogenesis, 
processing and channeling of the TRAP isoforms within these cells. Within this study, 
however not published, clonal cell populations were generated, whereof several clones were 
picked and further characterized within Paper III. Four clones with either high or low TRAP 
enzyme activity or protein expression in cell lysate or in the medium were used. The highly 
TRAP-overexpressing clonal cell population TRAP3
high
 was mostly applied in Paper I-IV as 
a representative for TRAP overexpression studies.  
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 TRAP knockdown in MDA-MB-231 breast cancer cells 2.4.2
The TRAP3
high
 cell population was furthermore used to create cell populations with a 
knockdown of TRAP, to directly study if effects are reversible. For this, MISSION® shRNA 
pLKO.1-puro Plasmid DNAs targeting rat TRAP were amplified in One Shot® TOP10 
Chemically Competent E. coli after heat shock transformation, purified, controlled for 
sequence identity by restriction enzyme digestions. Several plasmids were then transfected 
into TRAP3
high 
cells together with scrambled shRNA and selected by culture in puromycine-
containing medium. Knockdown efficiencies were assessed on RNA and protein level by 
qPCR and Western blotting, respectively. 
 Protein quantification and Localization studies 2.5
 Antibodies 2.5.1
 TRAP 2.5.1.1
As TRAP 5a and TRAP 5b molecules are exclusively distinguished by the presence or 
absence of a loop domain, present in TRAP 5a, respectively, it is not feasible to generate 
antibodies selectively detecting the TRAP 5b isoform, lacking the loop. Nevertheless, 
isoforms can be distinguished by combined application of an antibody detecting both TRAP 
isoforms and a loop-recognizing antibody selectively identifying monomeric TRAP 5a. 
Rabbit antibody sera against total TRAP or monomeric TRAP 5a were raised by 
immunization of New Zealand rabbits with either recombinant TRAP [266] or with the 
synthetic loop-peptide corresponding to amino acids 167–183 (DDFASQQPKMPRDLGVA) 
in the mouse TRAP sequence [213,266], respectively. High sequence homology allows for 
detection of TRAP derived from human, mouse and rat sources. 
 Others 2.5.1.2
Antibodies for β-Actin (mouse; Cat# 8224, Abcam), TGFβ2 (rabbit; Cat# 113670, Abcam) 
Integrin α5 (rabbit, Cat# ab150361, Abcam), Integrin β4 (mouse, Cat# ab29042, Abcam) and 
Cathepsin K (goat, Cat# ab77396) were purchased. A polyclonal antibody serum derived 
from New Zealand rabbits immunized with a peptide for Cathepsin K 
(C-KTHRKQYNNKVDE) as previously described [287]. 
 Immunocytochemistry (ICC) 2.5.2
For protein quantification and (co-)localization studies, as well as to determine cell 
proliferation (chapter III.2.7.2) in Paper III and IV, ICC was performed. Cells were grown in 
glass 8-well chambers (Labtek II, 154534). Medium was respectively enriched with blocking 
antibodies or inhibiting compounds or deprived from serum. The cells were fixed and stained 
with fluorescently labeled antibodies or based on click-chemistry. Confocal images were 
acquired in the Nikon A1+ confocal laser microscope system and image batch analysis 
performed in the ImageJ or Nis Elements Advance research imaging software 4.1.0 (Nikon). 
Confocal microscopy allowed for the generation of optical sectioning and increased 
resolution. Dependent on the measurements, different settings were applied during image 
acquisition and image analysis, regarding laser intensities, thresholding or signal intensities.  
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 Western blotting 2.5.3
In Paper I-IV, immunoblotting was applied to detect and quantify isoforms or precursor and 
mature forms of proteins. Briefly, lysates were prepared from cells that had conditionally 
undergone treatment. Cell pellets were lysed in RIPA buffer enriched with complete protease 
inhibitor cocktail and homogenized. Protein debris was removed by centrifugation and total 
protein content was determined. Respective conditioned media from cells prepared for lysis 
were separated from cell debris by centrifugation and immediately processed at 4 ˚C. Cell 
lysates and normalized volumes of corresponding medium were subjected to SDS-PAGE and 
transferred to PVDF membranes. Unspecific binding was blocked by 3% bovine serum 
albumin in PBS. Protein bands were detected by incubation with primary antibodies and 
infrared-labelled secondary antibodies, visualized in the Licor Odyssey Fc Imager system and 
quantified by densitometry with the Licor Image Studio software 3.1.4 (Licor Biosciences, 
Lincoln, NE, U.S.) upon normalization to β-Actin expression. 
 Enzyme activity measurements 2.6
 pNPP assay 2.6.1
Lysates prepared in a mild extraction buffer (0.15 M KCl, 0.1% Triton X-100) and fractions 
derived from Fast protein liquid chromatography (FPLC) were analyzed for TRAP-specific 
activity. Simultaneously, recombinant enzyme batches were assayed. Here, measurement of 
the released pNP product, emitting at a wavelength of 405 nm was used as an indirect 
correlation to released phosphate/TRAP activity. Addition of tartrate and molybdate allowed 
for discrimination from related TRAPs. The assay was conducted at a pH optimum for TRAP 
5b (pH 5.8) and conditionally enriched with sodium ascorbate and iron to reduce the irons in 
the active site of the enzyme (Fe
2+
/Fe
3+
) and thereby activate it. In Paper II, the assay was 
optimized to be adaptable to high-throughput format. 
 Malachite green 2.6.2
As an orthogonal assay, Malachite green was applied to complex with free phosphate derived 
from dephosphorylation of e.g. the experimental substrate ATP or the natural substrate 
osteopontin by TRAP in Paper I and II. As the malachite green assay is conducted in an 
acidic range, spontaneous phosphate release of pNPP contributed to high background levels 
and therefore excluded the use of pNPP as a substrate. This assay was besides using different 
substrates also measured at a different wavelength (630 nm), which allows for direct 
evaluation of assay interference, when compared to the pNPP assay, as performed in 
Paper II.  
 Functional cell experiments 2.7
Essential alterations in cell physiology that characterize cancer cells as malignant have been 
proposed as the hallmarks of cancer in 2000 and 2011 by Hanahan and Weinberg [13,14]. 
Common strategies to assess the ´behavior´ and capabilities of malignant cell lines related to 
these hallmarks are e.g. to assess morphological changes, replication potential and the ability 
to migrate and invade. To identify functional capabilities of cells with TRAP overexpression, 
several methods were set up, optimized or incorporated as part of Paper I-IV. 
 35 
III 
P
resen
t in
v
estig
atio
n
 –
 C
o
n
sid
eratio
n
s o
n
 th
e M
eth
o
d
o
lo
g
y
 
 Morphology  2.7.1
Morphological changes of cells are typical during dedifferentiation and in the course of 
progressing to a malignant state. Cancer cells often undergo (partial) epithelial-to-
mesenchymal transition (EMT) [201], accompanied by a cellular elongation, comparable to 
the morphology of fibroblastic cells. MDA-MB-231 cells are of elongated morphology and 
per se already fibroblast-like, when kept in cell culture. By measuring length to width ratios 
by image analysis in randomly selected cells, changes in elongation of cells with 
overexpression or knockdown of TRAP were assessed. 
 Cell growth 2.7.2
To assess the role of TRAP overexpression on the replicative potential of cancer cells we 
applied several different assays. By measuring cell growth with trypan blue, staining for 
acidic components such as nucleic acid and polysaccharides [288], we assessed both the 
potential of increased cell division and DNA production. Toluidine blue quantities were 
measured by absorbance at 630 nm of the dissolved color. A colony formation assay was 
used to evaluate the potential of cells growing under anchorage-independent conditions, 
increased hypoxia and limited access to nutrition, such as during the colonization of a 
metastatic site. For visualization, the DNA-intercalating dye Crystal violet was applied and 
image analysis consulted for the assessment of colony sizes and numbers. A proliferation 
assay, measuring the number of cells, going into S-phase by incorporation of the nucleic acid 
analog EdU, allowed us to test for multiplication of DNA-material.  
 Migration and Invasion 2.7.3
During several steps of the metastatic cascade, cancer cells become motile and invade into 
surrounding tissue. These capabilities were addressed applying both wound migration and 
transwell migration and invasion assays. Wound migration assays were conducted under live 
cell imaging in cell culture conditions, where cellular movement was recorded as an images 
series for 30 h under conditional treatment. Cells were first allowed to form confluent layers 
and migration induced by removal of cells by scratching. Migration in serum-free medium 
reduced the contribution of proliferation. For Transwell migration assays, the underside of the 
inserts was coated with basement membrane and extracellular matrix proteins. A serum 
gradient was adjusted by seeding cells in serum-deficient medium and adding serum-
containing medium in the lower well. Additional to the serum-gradient, it is likely that the 
coating attracts the cells both based on a chemo-gradient and allows direct contact through 
the membrane pores. For different proteins, specific times, when the assay was stopped were 
assessed and the amount of cells on the lower side of the insert quantified by Crystal violet 
stain dissolved and measured by absorbance at 600 nm.  
To test invasion, basement membrane-precoated transwell inserts were applied and cells 
allowed to invade for a specific amount of time through the layer towards the lower site of the 
insert. The invaded cells were then detached and quantified by luminescence. 
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 Phospho-proteomics and Proteomics analysis 2.8
Mass spectrometry-based proteomics and phospho-proteomics analyses were applied as part 
of a collaborative effort to investigate global changes of the protein and phosphoprotein 
network introduced by TRAP perturbation. A detailed elaboration on the method with respect 
to analytical depth and current protocol standards as well as interpretation of the results are 
discussed in Paper III and the doctoral thesis of Elena Panizza [289].  
Briefly, proteins were extracted in a detergent solution aimed to extract a variety of proteins, 
including cellular and membrane proteins and the proteins were digested by trypsination. For 
multiplex analysis either SILAC or TMT labeling was consulted. In case of SILAC labeling, 
the cells were first cultured in medium containing stable heavy isotope or light isotope-
labeled amino acids. For TMT labeling, peptide samples were incubated after digestion with 
TMT10plex reagents allowing for similar analysis of up to 10 samples. Phosphoproteins and 
proteins were pre-fractioned by High Resolution Isoelectric focusing (HiREF) to increase the 
analytical depth. To enrich for phosphorylation sites conditionally an ultra-acidic strip was 
applied. Peptides were pre-fractioned and analyzed in a LTQ Orbitrap Velos mass 
spectrometer. Computational methods, such as hierarchical clustering based on Euclidian 
distance, Gene ontology analysis (Gorilla) and network analysis (Cytoscape, STRING) were 
conducted to analyze and interpret the results for the formulation of biological hypotheses. 
 Molecular docking studies 2.9
In Paper I and II, molecular modelling of selected compounds was performed within 
collaboration with the company Biognos AB, Gothenburg. Receptor structures were prepared 
in a protein preparation wizard (Maestro, LeadIT), based on the mammalian crystal structures 
of human (1WAR) and rat TRAP (1QFC) [52,53]. The inhibitors were docked to assess 
putative binding modes into the active site of the TRAP molecule with the program Glide or 
FlexX. Poses were scored using HYDE. 
Based on missing knowledge about co-crystallization of the molecules with the enzyme and 
limitedly defined crystal structures (2 Å and 2.7 Å, respectively), all binding modes described 
are de novo and putative. Nevertheless, binding into the active site suggests potential 
interaction points and modes of inhibitory action. 
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Figure 12 TRAP isoform expression in control 
and TRAP-overexpressing MDA-MB-231 cells 
under treatment with 200 µM 5-PNA for 24 h. 
 Results and Discussion 3
 Can potent and specific TRAP inhibitors be identified and applied? 3.1
Protein phosphorylation plays a key role in a variety of physiological processes and 
deregulation can be coupled to pathological conditions. Orchestrating a variety of cellular 
functions via their activity to phosphorylate and dephosphorylate signaling mediators, both 
kinases and phosphatases represent interesting candidates for drug targeting.  
Protein kinases have been the more popular drug targets, whereas phosphatases are 
underrepresented in the development of inhibitors and clinical trials. Phosphatases have been 
earlier categorized as undruggable targets as not fitting into the conventional “lock and key” 
model [290]. Nonetheless, advances in the development of phosphatase inhibitors have been 
made with the progression of knowledge about structural features, computational modelling 
programs or enhanced libraries [290]. 
Tartrate-resistant acid phosphatase (TRAP) is a ubiquitously expressed enzyme and cellular 
location is attributed to vesicular like structures, such as lysosomes. Furthermore, TRAP is an 
enzyme containing a redox-sensitive bimetal iron center in the active site and irons 
susceptible to reduction or oxidation affect TRAP´s activity [20]. In the conventional view, 
these characteristics make TRAP a challenging drug target, nevertheless, an attractive drug 
target, due to its involvement in the pathogenesis of diseases, such as osteoporosis and 
cancer. Finally yet importantly, limitations that would render inhibitors inapplicable in a 
clinical setting do not necessarily exclude the use of the compound to target functions in a 
cellular system. 
 Characterization and identification of TRAP inhibitors 3.1.1
Feder et al. identified 5-PNA next to two other compounds as a TRAP inhibitor by fragment-
based lead discovery [278]. When these compounds were retested, 5-PNA was the only 
compound inhibiting recombinant human and rat TRAP in Paper I. Kic values for the 
inhibition of TRAP could be reproduced from various sources and with the application of 
several possible substrates (~100 µM). Importantly, 5-PNA inhibited TRAP 5b and TRAP 5b 
activity in lysate, selectively. 
In TRAP-overexpressing MDA-MB-231 breast 
cancer cells, TRAP is early in the secretory 
pathway diverged to provide a pool of 
monomeric TRAP 5a destined for cleavage 
[214]. It could be excluded that the reduction 
of TRAP activity by 5-PNA derives from an 
inhibition of cleavage or modulated secretory 
pathway. Either of these possibilities would 
result in higher levels of the low active TRAP 
5a at the expense of TRAP 5b. 5-PNA did not 
exert any of these effects, further assessing the 
specificity of 5-PNA on inhibition of TRAP 
activity (Figure 12).  
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Next to the characterization of 5-PNA, small molecule library screening was applied to 
identify additional compounds with a potential for TRAP enzyme inhibition (Paper II). In 
this approach, among several thousands of compounds, meticulously assessed for drug-like 
characteristics and promiscuous hitters, 22 compounds and thereof six cluster representatives 
were filtered for inhibition of TRAP 5a and 5b activity in a range of ~1-100 µM.  
As 5-PNA rendered only potent for TRAP 5b and previous studies did not differentiate 
between the TRAP isoforms, our interest focused also on the identification of isoform-
selective/unselective inhibitors. Additionally, the compounds were assessed for inhibition of 
the recombinant enzymes in either mixed-valent or oxidized state of the iron atoms in the 
active site. No previous study has addressed possible differences in inhibition dependent on 
the redox state of the active site. The majority of activity assays was performed under non-
reducing conditions [63,241,270,273,278], which increases the likeliness that the enzyme was 
in the oxidized state. Additionally, in Paper II, all compounds had a higher potency of 
inhibiting TRAP 5b and the enzyme when the iron atoms were oxidized. In contrast, 5-PNA 
did show minimal preferences for inhibiting the TRAP 5b enzyme in the mixed-valent state 
(unpublished results).  
Different modes of inhibition in different redox states could suggest a modulation of the 
active site dependent on redox state of the irons. Compounds can commonly render as 
unspecific inhibitors by oxidizing enzymes with redox-active sites. As all six cluster 
representatives displayed more potent inhibition on the oxidized enzyme, it is unlikely that 
they act via changing the redox activity of TRAP. 
5-PNA (Paper I), and the six novel compounds identified in Paper II, were subjected to 
molecular docking studies to predict a possible binding mode to the active site of TRAP. 
5-PNA, which was already proven to bind into the active site by X-ray crystallography, 
interacted with the iron atoms in a fashion similar to substrates (Paper I). In contrast to that, 
all six compounds in Paper II bound into the active site without any close interaction with 
the iron atoms. 
 Application of the TRAP inhibitors in a cellular system 3.1.2
The applicability of 5-PNA and the novel six TRAP inhibitors in a cell system was 
investigated by assessing their potential to block TRAP-dependent breast cancer cells 
characteristics. In Paper I, 5-PNA inhibited TRAP-dependent migration and invasion at 
200 µM without inducing cytotoxicity up to mM concentrations. In Paper III, TRAP-
dependent proliferation and increased expression of TGFβ promoted by TRAP was further 
abrogated by 5-PNA.  
Furthermore, RAW264.7 macrophages treated with receptor-activator of NFκB ligand 
(RANKL), upregulate TRAP expression. When TRAP was inhibited with 200 µM 5-PNA in 
these cells, RANKL-stimulated migration was abrogated [241].  
Amongst the six novel TRAP-inhibitors of Paper II, only the compound CBK289001 was 
able to inhibit TRAP-dependent migration of MDA-MB-231 cells, similarly to 5-PNA. The 
control cells were not affected and the cells did not show any obvious signs of cytotoxicity. 
Why only one compound inhibited migration in the cell system, whereas all six compounds 
inhibited TRAP in silico can currently not be explained by molecular docking studies but 
could eventually be resolved by molecular dynamic simulations. 
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 Advantages and limitations of the TRAP inhibitors 3.1.3
Earlier, flavonoids reduced secreted TRAP activity and osteoclastic pit formation with 
IC50 <10 µM, while maintaining cell viability [270]. Polyphosphates with long chain lengths 
inhibited TRAP phosphatase activity at IC50 < 5 µM. Nevertheless, concentrations of 1 mM 
were applied for the reduction of osteoclastic pit formation [273]. Finally, the gold 
coordination compound AubipyOMe inhibited both isoforms of TRAP at IC50 < 2 µM and 
TRAP at IC50 < 4 µM, when applied to cells. When treating RANKL-stimulated RAW264.7 
macrophages with 80 nM of the gold compound, migration was inhibited without exerting 
any cytotoxic effects up to mM concentrations [241].  
Despite previously suggested inhibitors displaying higher potencies in Kic and IC50 values, 
5-PNA and CBK289001 are one of the first inhibitors effective in the inhibition of TRAP-
dependent cancer cell functions. Furthermore, 5-PNA is a TRAP 5b selective inhibitor, 
whereas CBK289001 was able to inhibit both isoforms. 
In spite of testing for and applying a library with drug-like characteristics in Paper I and II, 
the current results bear limitations. 
5-PNA was tested for its activity on closely related phosphatases, such as PP2A and PP1 and 
cytotoxic effects up to high concentrations in the MDA-MB-231 cell line. It was further 
assessed for drug-like characteristics based on prediction analysis and binding shown by 
X-ray crystallography. On the other hand, CBK289001 was shown to be non-promiscuous 
and did not belong to classes of PAINS, REOS or aggregators, but has not yet been 
experimentally tested for promiscuity, cytotoxicity or binding. Thus, the TRAP-inhibitors 
need to be further assessed for unwanted interactions with other molecules and their 
cytostatic effects in a variety of cancer cell lines. Moreover, comparably high concentrations 
of the inhibitors were necessary to result in inhibition of the recombinant enzyme and in the 
abrogation of TRAP-dependent functions. The latter could be explained due to a ´non-
optimized´ structure, as e.g. 5-PNA is only a compound fragment. Limited cell permeability 
and delivery to the enzyme site or a less potent binding with active site residues could further 
be optimized by structural modifications. Further tests and chemical optimizations are 
therefore necessary to allow for the multifunctional application of 5-PNA as a potent and 
specific TRAP inhibitor. Last but not least, studies on structural analogs of CBK289001 and 
5-PNA can help in the development and chemical optimization for more potent substances. 
 Does TRAP make cancer cells more aggressive and likely to 3.2
metastasize? 
A growing body of evidence has been accumulated in the recent years supporting the idea 
that TRAP 5b serum levels from bone lesions do not only derive from resorbing osteoclasts. 
Even that the knowledge about TRAP expressing tumors, i.e. leukemic tumors was not new 
[291], detection of TRAP expression in several cancer cell lines and primary cells 
underscored the involvement of TRAP in cancer cell function [259,260].  
TRAP was associated to disease progression, as levels were high in metastatic lesions of the 
breast, ovary, skin, prostate, lung and kidneys [259,264]. Furthermore, expression of TRAP 
showed to be increased with progressive disease status [82,259–261]. Conclusively, several 
studies attributed TRAP expression a significant role in the development of the disease, as 
correlated to a variety of clinically relevant parameters and addressed in mouse models. 
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Figure 13 Integrin α5 (ITGα5) and β4 (ITGβ4) expression in control 
and TRAP-overexpressing MDA-MB-231 breast cancer cells. 
Specifically, TRAP was associated to a shortened patient survival, lymph node metastasis, 
peritoneal dissemination, TNM stage, probability of recurrence, tumor size and 
encapsulation, microvascular invasion and tumor differentiation in melanoma, hepatocellular 
carcinoma and gastric and lung cancer [82,261–263]. 
In vitro studies assessed the effects of TRAP expression on the cellular level. For instance, 
TRAP overexpression increased invasion of melanoma cells and downregulation reduced the 
potential to form colonies in soft agar [82]. In hepatocellular carcinoma cells, TRAP 
stimulated cell migration and invasion [261]. Similarly, overexpression of TRAP in 
metastatic breast cancer cells promoted proliferation, anchorage-independent growth, 
migration and invasion (Paper III). Cellular morphology was elongated, whereas TRAP 
overexpression resulted in cell rounding and spreading in previous studies [82,214]. 
Interestingly, morphology and migration were regulated level-dependently when comparing 
TRAP-overexpressing clones with different expression and activity levels, whereas 
proliferation and invasion were upregulated independent of the levels of TRAP protein and 
activity (Paper III). Migration was moreover selectively increased on extracellular matrix 
proteins osteopontin, fibronectin, collagen IV and laminin. Proliferation was furthermore 
increased compared to control cells after serum starvation. Unpublished results support a 
possible upregulation of the EMT-markers Snail and Vimentin. Abrogation of TRAP by 
small chemical inhibition or knockdown reversed the effects in Paper I, II and III.  
In summary, cellular characteristics associated to metastasis were positively regulated in 
several cancer cells and can directly be associated to the data acquired from clinical studies. 
TRAP upregulation promotes a metastatic phenotype of cancer cells that could ultimately be 
coupled to increased spreading and infiltration. 
 How does TRAP change the cellular signaling network? 3.3
 Signaling pathways affected by TRAP  3.3.1
Melanoma cells overexpressing TRAP were shown to express reduced levels of focal 
adhesion kinase (FAK) autophosphorylation at Tyr 397 and tyrosine phosphorylation of 
Paxillin at Tyr 118. These results could generally suggest an involvement of integrin 
signaling. Also in Paper III, downregulation of integrin β4, integrin α6 and upregulation of 
integrin α5 upon TRAP upregulation could be observed by proteomics analysis and verified 
by immunoblotting (Figure 13, unpublished data).  
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TRAP signaling independent of cancer cells was earlier associated with TβR-interacting 
protein-1 (TRIP-1). TRIP-1 is an intracellular protein that is phosphorylated by TβRII kinase 
[203]. Intracellular interaction of TRIP-1 with TRAP was activating TβRII and osteoblast 
differentiation through the SMAD-2/3 pathway at sites of prior bone resorption [24]. 
Independent of TRIP-1, Paper III could point out that TRAP overexpression is modulating 
TGFβ signaling by upregulating TGFβ2 and TβRI, shown by (phospho-)proteomics analysis. 
CD44 phosphorylation in the intracellular domain was furthermore highly upregulated. CD44 
has been related to TRAP via its substrate OPN, which is a ligand for CD44 [81,114]. 
Moreover, CD44 can with its intracellular domain interact with TβRI [158], thereby 
stimulating multiple signaling pathways mediating, e.g. migration. Indeed, blocking of 
TGFβ2 and TβRI/II activity was able to abrogate the promotive effect on migration in 
Paper III, whereas exclusive blocking of CD44 was not sufficient (Figure 14).  
Additionally, several proteins associated with extracellular matrix modulation and cell 
adhesion were regulated by TRAP overexpression/downregulation. These included proteins, 
such as β-Catenin-1, MMPs, collagens, laminin, lumican, vitronectin, thrombospondin 5, 
moesin (ERM family) and ROCK-1. Importantly, TRAP is already known to be involved in 
extracellular matrix regulation during bone remodeling.  
Despite the fact that Paper III verified only a very limited amount of signaling mediators and 
connections, it provides a huge set of data, including relevant candidates that have either 
previously been connected to TRAP or with functions associated to TRAP. The reported 
network of proteins regulated upon TRAP perturbation, provides a starting point to further 
dissect molecular signaling sequences induced upon TRAP overexpression.  
Figure 14 Signaling mediating metastatic-related cancer cell functions 
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 Possible substrates of TRAP in cancer cells? 3.3.2
Phospho-proteomics was used in Paper III to depict phosphorylation events modulated by 
TRAP perturbation. It needs to be noted that the applied method of phosphosite enrichment 
was based on high isoelectric focusing (HiREF) on an ultra-acidic strip. This results in 
enrichment, mainly detecting multiple phosphorylated peptides or peptides with several 
acidic residues. Furthermore, dephosphorylated peptides are generally low in abundance, 
limiting the detection level and spectrum of phosphopeptides (compare thesis of Elena 
Panizza, [289]), thereby possibly excluding significant and direct substrates of TRAP. 
Nevertheless, the phosphorylation sites significantly regulated upon TRAP overexpression 
were associated with GO molecular functions, such as cell adhesion molecule binding, and 
cadherin binding. They were further allocated to the GO cell components nuclear part, cell 
junction, anchoring junction, adherens junction and cell-substrate junction. Despite including 
upregulated phosphoevents, these data corroborate a role of TRAP in cell adhesion and 
cytoskeletal modulation upon dephosphorylation of un-annotated substrates. 
Interestingly, two serine phosphorylation sites of integrin β4 (1448, 1451), three 
phosphorylation sites of plectin (S4253, 4476, 4254), a protein interlinking different elements 
of the cytoskeleton and two phosphorylation sites of ROCK1 (S1105, S1102) are candidates, 
associated with cell migration and cytoskeletal changes. 
Similarly to tyrosine peptides being able to be dephosphorylated by TRAP, melanoma cells 
overexpressing TRAP displayed modulations in tyrosine phosphorylations [82].  
Interestingly, despite osteopontin (OPN) being proposed as a main substrate for TRAP, it was 
not identified as a significantly downregulated phosphoevent. OPN is an acidic protein with 
an abundance of negatively charged amino acids [292]. Thus, it is unlikely that the previously 
mentioned detection limits of the phosphosite enrichment are solely responsible for OPN not 
being detected. Nevertheless, OPN was earlier shown to be a substrate present in the 
extracellular matrix for TRAP [78–81]. This could possibly explain why cellular levels were 
not changed, possibly due to differences in localization. 
Localization differences have to be further considered with regard to phosphosubstrates, as 
TRAP is stored in vesicular compartments, e.g. making a direct interaction with substrates, 
such as PAX and FAK [82] unlikely. Earlier, TRAP was reported to be an enzyme with low 
substrate specificity and it was suggested that localization and posttranslational control would 
define its functional reach. This notion could be further supported by immunohistochemistry 
staining of monomeric and total TRAP from Paper IV, where a disturbance of TRAP 
cleavage resulted in relocalization within the cellular compartments. Also Zenger et al. 
showed earlier, that MDA-MB-231 cells overexpressing TRAP diverted TRAP to be cleaved 
early in the secretory pathway [214].  
 Is Cathepsin K involved in the proteolytic processing of TRAP 5b? 3.4
Previous studies applying in silico experiments, osteoclasts and Cathepsin knockout mice 
have led to the hypothesis of Cathepsin K (CtsK) being involved in processing of TRAP. 
Whereas cleavage by other unidentified enzymes was suggested to be necessary for further 
processing by Cathepsins, CtsK was hypothesized to mediate the final step of TRAP 5b 
processing. 
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Figure 15 CtsK expression in cancer cell lines 
Initially, several enzymes were tested for their ability to generate and cleave TRAP 5a to 
TRAP 5b in silico (chapter II.2.3.2.3). Amongst them, serine/threonine proteinases, MMPs 
and Cathepsins were tested [30,61,68]. Amino acid sequencing resolved that processing of 
both bone and CtsK-cleaved TRAP 5b was identical in N- and C-terminal sequences, 
whereas Cathepsin L (CtsL) cleavage removed fewer amino acids in the N-terminal site [68].  
 Codependent regulation of CtsK and TRAP 3.4.1
A variety of results stimulated the idea of a concerted regulation of CtsK and TRAP. Both 
molecules are co-expressed in the osteoclast microenvironment and several compartments of 
the osteoclast [68]. In the latter, CtsK was predominantly expressed amongst the cathepsins, 
whereas CtsL was expressed at much lower levels [68,91,109]. Furthermore, both CtsK and 
TRAP enzyme are involved in the bone degradation process by either degrading collagen 
type I or dephosphorylating non-collagenous bone matrix proteins, such as the 
phosphoproteins osteopontin or osteonectin, respectively. Absence of CtsK in knockout mice 
was further compensated by upregulation of TRAP activity and mRNA, suggesting a possible 
feedback loop [92]. In contrast, other reports supported a regulation by different mechanisms, 
as CtsK and TRAP were recruited to the resorption lacuna of activated osteoclasts in a 
sequential manner [108]. 
A variety of cancers display upregulation of CtsK [96–99], and CtsK levels were significantly 
increased when compared to CtsL [97]. Nevertheless, studies assessing a possible correlation 
of TRAP and CtsK levels in patients are lacking to date. In Paper IV, we could show that 
pre- and mature CstK was expressed in MDA-MB-231 cells. Unpublished results 
demonstrate further expression of both CtsK forms in other cancer cell lines (Figure 15). 
A TRAP-dependent regulation of CtsK, reverse to what was denoted in osteoclasts could not 
be argued for, given that TRAP upregulation or inhibition by 5-PNA did not elicit any 
obvious changes in CtsK expression (unpublished data). Treatment with the CtsK inhibitor 
Odanacatib did neither increase the levels of total TRAP in the TRAP-overexpressing cells.  
 Mechanism of CtsK-dependent cleavage of TRAP 3.4.2
FPLC can be used to separate monomeric and differentially processed TRAP forms [68]. 
Commonly, three peaks can be observed, where the first peaks at lowest salt concentrations 
represents the monomeric TRAP 5a isoform (L1a, L1b) and two following peaks at higher 
salt concentrations represent differently cleaved versions of TRAP 5b. For instance, when 
cell lysates were applied, e.g. from osteoclasts or TRAP-overexpressing breast cancer cells, 
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several forms of cleaved TRAP were identified, such as and intermediate product (L2) and a 
fully cleaved (L3) TRAP 5b form (Figure 16 A, lysate –E-64) [92,214].  
Importantly, this intermediate form (L2) was increased when cysteine proteinases were 
inhibited by E-64 in RAW264.7 cells [92] or TRAP-overexpressing breast cancer cells 
(Figure 16 A, lysate +E-64) [214]. Increased levels of the intermediate TRAP 5b form were 
further detected in bone lysates of CtsK knockout mice [92].  
In Paper IV the involvement of CtsK could be pinpointed, by treating TRAP-overexpressing 
MDA-MB-231 cells with a CtsK-specific inhibitor. Even that it remains to be shown that 
Odanacatib treatment elicits a similar intermediate peak in the FPLC elution profile, it 
increased the 23 kDa specific band reminiscent to the blotting profile of the FPLC-purified 
intermediate TRAP 5b form in E-64 treated cells (Figure 16 B, L2 +E-64).  
 TRAP trafficking affected by CtsK cleavage 3.4.3
Interestingly, next to changes in TRAP processing intracellularly, a reduction in TRAP 5a 
protein secretion could be seen upon CtsK-specific inhibition in Paper IV. Similarly, CtsK 
deficient knockout mice were unable to secrete monomeric TRAP 5a [92]. 
The change in secretion in TRAP-overexpressing breast cancer cells was coherent with 
intracellular differences in TRAP localization. Changes in localization of TRAP have 
previously also been detected in osteoclasts of CtsK knockout mice [92]. Whereas hardly any 
colocalization was seen of total and monomeric TRAP 5a in wildtype mice, total and 
monomeric TRAP 5a was evenly distributed in CtsK knockout mice. This is similar to the 
TRAP-overexpressing cells that were treated with the CtsK-specific inhibitor Odanacatib 
(Paper IV). Monomeric TRAP 5a was generally retained in vesicular-like structures, whereas 
total TRAP (representing supposedly TRAP 5b) showed diffuse distribution. Here CtsK 
Figure 16 Effect of the cysteine proteinase 
inhibitors E-64 on proteolytic processing of 
TRAP expressed by MDA-C11 cells. (A) Elution 
pattern from FPLC Heparin chromatography of 
cellular TRAP expressed by MDA-C11 cells 
following treatment with E-64. Lysates 
containing equal amounts of protein were loaded 
onto the column for each group. Horizontal bars 
under the peaks highlight the fractions pooled for 
further analysis of the peaks. (B) Western blot 
analysis of eluted intracellular TRAP peaks of 
MDA-C11 before and after treatment with E-64. 
Reprinted with permission from Zenger S, Ek-
Rylander B, Andersson G. Biogenesis of tartrate-
resistant acid phosphatase isoforms 5a and 5b in 
stably transfected MDA-MB-231 breast cancer 
epithelial cells. Biochim. Biophys. Acta - Mol. 
Cell Res. Elsevier B.V.; 2010;1803:598–607. 
Copyright: ©2010 
A 
B 
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inhibition only affected total TRAP staining, by reducing the diffuse distribution and 
inducing retention in vesicular-like structures, i.e. similar to the TRAP 5a –like pattern. This 
altogether suggests that CtsK enzymatic activity influence the localization of cleaved TRAP 
5b in cells.  
 Other enzymes involved in TRAP cleavage 3.4.4
The presence of intermediate cleaved forms of TRAP 5b in a variety of conditions is 
suggesting a common mechanism of TRAP processing. Nevertheless, CtsK could not be 
exclusively claimed responsible for the complete cleavage of TRAP. This was for instance 
supported by the observation that cleaved TRAP 5b was still present in CtsK-deficient mice 
[92]. Also both Cathepsin K and L enzymes were earlier shown to similarly cleave TRAP in 
a two-step process in vitro [68], suggesting the possible involvement of several enzymes in 
the cleaving sequence. CtsL, present at low quantity in acidic vesicles, was then suggested to 
be responsible for the initial processing of TRAP. TRAP would then be further processed 
upon fusion with vesicles containing CtsK. Nevertheless, neither complete blocking of 
Cathepsins by E-64, nor selective blocking of CtsL was sufficient to inhibit full cleavage of 
TRAP in several cell types [214,293], ruling out that sequential processing by Cathepsins 
would be sufficient for full cleavage of TRAP. Other enzymes are potentially involved in 
complete cleavage of TRAP and remain to be identified. 
 Parameters affecting CtsK-dependent cleavage of TRAP 3.4.5
As isoform processing and secretion displays to be different in various cell types, further 
suggestions have been made regarding factors determining TRAP cleavage.  
For instance, increasing levels of Cathepsins added to recombinant TRAP resulted in 
increasing levels of fully cleaved TRAP 5b concomitant with a reduction in intermediate 
TRAP 5b [68]. This led to the assumption that relative levels of CtsK and CtsK activity in the 
compartments could determine the efficiency of TRAP processing. High levels of CtsK are 
reported in osteoclasts, which associate with increased TRAP 5b levels in the resorption 
lacuna. Furthermore, we could show high percentage of colocalization and similarly high 
levels of TRAP 5b in TRAP-overexpressing cells. Coherently, after a recovery period of 24 h 
after treatment, the reduction in Odanacatib concentration (reversible CtsK inhibitor)  resulted 
in a reversible effect on TRAP processing and secretion in Paper IV. 
Finally, also other parameters could steer activation of TRAP by cleavage. As increased 
TRAP 5b ratios were predominantly seen in ´TRAP-overexpressors´, such as osteoclasts, it is 
speculated that TRAP 5a cleavage mainly occurs in cells with high TRAP expression. As we 
could not detect any difference in mature CtsK ratios in the TRAP-overexpressing cells, the 
determining factor could lie in the initial processing of TRAP that might be regulated by 
TRAP levels.  
Finally, the activation of TRAP is dependent on localization, as TRAP is mainly stored in 
vesicular structures. A site-dependent role for CtsK in TRAP processing was for instance  
also observed in bone tissue of mice [294].  
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 Is TRAP 5b isoform relevant for the development of the cellular 3.5
phenotype observed in TRAP-overexpressing cells? 
The different TRAP isoforms have been proposed for their relevance in different diseases and 
functions (chapter II.7.3 and II.7.4). Posttranslational modifications, such as proteolytical 
cleavage, are highly regulated mechanisms to control the exertion of protein functions. When 
these processes are dysregulated, pathological conditions commonly appear.  
With reference to the similarities in its function in osteoclasts, TRAP 5b was regarded as the 
isoform being more likely involved in conferring cancer cell features. Similar to the matrix 
degradation necessary for cellular invasion, enzymes are secreted by the osteoclasts to 
degrade the surrounding bone matrix. Here, TRAP was secreted and rapidly cleaved by 
extracellular enzymes to dephosphorylate non-mineralized phosphorylated bone matrix 
proteins, such as osteopontin or osteonectin [295]. Additionally, TRAP 5b was involved in 
the attachment and migration of osteoclasts on the phosphorylated bone matrix [78,80]. 
With the detection of TRAP expression in cancer cells [82,259–261], TRAP 5b levels 
suggested as serum markers of cancer patients with bone lesions, were no longer only 
attributable to increased activity of osteoclasts, but also likely to be derived from cancer cell 
populations.  
 Isoform expression in cancer cells 3.5.1
Most cancer-related studies commonly did not specify the respective expression and 
contribution of either isoform and only Zenger et al. reported about isoform differences in 
breast cancer [264]. When analyzing the distribution of TRAP isoforms, it was found that 
cancer cells mainly expressed TRAP 5a, whereas 5b was present in stromal cells. Also in a 
majority of cancer cell lines, mainly TRAP 5a expression was detected intracellularly (Figure 
17).  
Figure 17 TRAP expression in lysate and medium of various cancer cell lines. Cell pellets and conditioned 
media were kindly provided by the groups of Prof. Mikael Björnstedt (IGROV1, A375, Huh7, HepG2, Hep3B, 
Panc1), Assoc.Prof. Katalin Dobra (B6FS) and Assoc.Prof. Maria Shoshan (A2780, SKOV3). 
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Contrary to these observations, the levels of TRAP 5b/5a were significantly increased in the 
TRAP-overexpressing cells used as a model system for this thesis (Paper IV). Importantly, 
the levels of TRAP 5a were not significantly changed within the parental and TRAP-
overexpressing cells. Hence, TRAP 5b activity in TRAP-overexpressing cancer cells was 
hypothesized to be responsible for the promotion of aggressiveness. TRAP-overexpressing 
cells displayed cell characteristics commonly associated to metastasis that were less 
pronounced in the control cells (Paper III). 
Given that most cell lines with TRAP expression do not process TRAP 5a in a similar 
manner as TRAP-overexpressing MDA-MB-231 cells, intracellular TRAP is thus likely to be 
cleaved under unknown but specific circumstances, as previously noted in chapter III.3.4.5. 
  Inhibition of TRAP 5b-activity  3.5.2
A limited amount of studies investigating the role of TRAP in cancer cells modulated the 
expression and activity of TRAP. Hereby strategies such as blocking antibodies, siRNA, 
shRNA-mediated knockdown or upregulation models were applied [82,230,261]. 
Importantly, we could expand these data in Paper I and III by inhibiting the activity of the 
TRAP 5b isoform with 5-PNA next to up- and downregulating the TRAP (and considerably 
the TRAP 5b) protein. Metastasis-related functions, such as proliferation, migration, invasion 
and overexpression of TGFβ2 could be normalized upon 5-PNA treatment. This 
normalization was associated to a reduced enzymatic activity intracellularly, where mostly 
TRAP 5b contributes to cellular activity.  
Even that CBK289001, the compound identified as a TRAP-inhibitor in Paper II, inhibited 
both isoform activities under non-reducing conditions, TRAP 5b was favored when activated 
by reduction. Additionally, TRAP 5b was more potently inhibited than TRAP 5a under both 
conditions. CBK289001 abrogated TRAP-dependent migration, similarly to 5-PNA, level-
dependently. These data altogether underscore that inhibition of TRAP 5b activity by two 
independent compounds is able to normalize the TRAP-dependent phenotype in cancer cells. 
Initially, it was hypothesized that inhibition of TRAP processing by Odanacatib would 
increase TRAP 5a levels concordantly with reduced TRAP 5b levels. Nevertheless, CtsK 
inhibition was not sufficient to inhibit TRAP cleavage fully or reducing TRAP 5b/5a levels in 
Paper IV. In contrast, treatment of TRAP-overexpressing cells with Odanacatib increased the 
23 kDa TRAP 5b, possibly attributable to an intermediate cleaved from of TRAP 5b. 
Importantly, the intermediate form of TRAP 5b did not elicit a reduced activity, as total 
TRAP activity in lysate was unchanged (Paper IV). Also in a previous publication, total 
TRAP activity, calculated by the sum of FPLC peak activity derived from intermediate and 
fully cleave TRAP 5b after E-64 treatment, was similar to the untreated condition [214]. 
Addition of CtsK to the intermediate cleaved TRAP 5b form was not able to further increase 
activity [214]. Related to indifferent changes in phosphatase activity, the difference in the 
intracellular TRAP 5b profile did not result in functional changes, such as modulation of 
migration (Paper IV).  
Nevertheless, it should be noted that treatment with the CtsK inhibitor Odanacatib resulted in 
a differential localization of the intermediate TRAP 5b within the cell. This would 
consequently have a pivotal effect on subcellular substrates and signaling mediators available 
to TRAP activity. Finally yet importantly, migration was level-dependently regulated by 
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TRAP (Paper III). It can therefore not be excluded that despite similar activity and 
differential location of the intermediate TRAP 5b form, levels of the fully cleaved TRAP 5b 
remaining after CtsK inhibition are sufficient to promote migration. Neither can one exclude 
that other functions, such as growth and invasion would similarly be unaffected by changes in 
the cleavage pattern of TRAP. 
 Contribution of extracellular TRAP 3.5.3
TRAP is processed and secreted by a variety of cells (chapter II.7.1 and II.7.2). Importantly 
most cell types, such as TRAP-overexpressing MDA-MB-231 breast cancer cells (Paper I, 
III and IV) and macrophages secrete monomeric TRAP 5a, whereas the monomeric TRAP 
5a secreted into the resorption lacuna by osteoclasts is rapidly processed to the cleaved TRAP 
5b by osteoclast-derived CtsK (Figure 5 and 11). Most other cancer cells with TRAP 
expression were not reported or shown to secrete TRAP (Figure 17) [82,259–261]. As in the 
parental MDA-MB-231 breast cancer cells TRAP 5a was secreted, this alternative supply of 
TRAP can similarly be attributed to eliciting characteristics specific for TRAP-
overexpressing cells.  
TRAP 5a has so far mainly been reported to function as a growth and differentiation factor 
[242], which could disclose, why growth and proliferation was also promoted in TRAP 
overexpressing cells in Paper III. As binding to the surface of adipocytes and endocytosis 
was shown [224], it cannot be excluded that secreted TRAP 5a could act as an autocrine 
factor that stimulates proliferation/migration/invasion via a receptor-mediated signaling 
process. Currently, limited knowledge is present regarding possible receptors that TRAP can 
bind to, but attempts have been made to identify them [223]. Also, unpublished studies, 
performed by Christina Patlaka (personal communication), showed that TRAP 5a can bind to 
the surface of MDA-MB-231 cells. 
Treatment with 5-PNA reduced proliferation, migration and invasion in TRAP-
overexpressing cells (Paper I and III). This inhibitor is inefficient in inhibiting TRAP 5a 
activity, but can bind to both isoforms, shown by docking studies and crystallography [278]. 
Assuming that TRAP 5a exerts its role via binding, we cannot exclude that, despite 
inefficiency in inhibiting the activity of TRAP 5a, 5-PNA is also able to block surface-
receptor binding and thereby inhibiting the possible TRAP 5a role.  
Contradictory to a role of extracellular TRAP 5a, however, addition of TRAP 5a to the 
parental cells left migration unchanged (Paper IV). Concentrations of TRAP 5a were adapted 
to levels similar to the secreted levels in TRAP-overexpressing MDA-MB-231 cells. 
Additionally, the reduction in secreted TRAP upon treatment with Odanacatib failed to 
change, i.a. reduce the migration of TRAP-overexpressing cells.  
In summary, it can be excluded that secreted TRAP 5a has an effect on TRAP-dependent 
migration. A possible autocrine signaling of TRAP 5a and its contribution to growth and 
proliferation or invasion in cancer cells remains to be investigated. 
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 Conclusions 4
 
Can potential and specific TRAP inhibitors be identified and applied? 
 5-PNA is a small molecule inhibitor despite low sensitivity specific for TRAP 5b 
activity and applicable in a cellular system 
 By small molecule screening, six potential candidates for TRAP 5a and TRAP 5b 
inhibition, and especially CBK289001, were outlined that can be further used to 
develop more potent inhibitors of TRAP 
 
Does TRAP make cancer cells more aggressive and likely to metastasize? 
 Overexpression of TRAP promotes metastasis-related cell properties in MDA-
MB-231 breast cancer cells that can be reverted by TRAP inhibition or knockdown. 
 
How does TRAP change the cellular signaling network? 
 Overexpression of TRAP significantly increases levels of TGFβ2, TβRI and 
intracellular phosphorylation of CD44, attributable for increased migration and 
proliferation in MDA-MB-231 breast cancer cells. 
 Overexpression of TRAP modulates Gene ontology terms “Cellular adhesion”, 
“Extracellular matrix modulation” and “Mitochondrial termination” 
 Overexpression of TRAP downregulates a variety of phosphosites, representing 
possible candidates as TRAP substrates 
 
Is Cathepsin K involved in the proteolytic processing of TRAP 5b?  
 Cathepsin K is involved in proteolytical processing of TRAP 5b from an intermediate 
form to the fully cleaved from.  
 The intermediate TRAP 5b form has most likely a different cellular localization of 
TRAP, similar activity and a promotive effect on cell migration. 
 
Is TRAP 5b isoform relevant for the development of the cellular phenotype? 
 TRAP 5b intracellular, but not TRAP 5a extracellular is responsible for increased 
migration in TRAP-overexpressing MDA-MB-231 breast cancer cells. 
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 Future perspective 5
In the curse of targeted cancer therapy, well-established prognosis and prediction markers are 
pivotal to enable patient-focused therapy. 
In this thesis, a substantial contribution has been made to the knowledge of the role and 
mechanism of TRAP during cancer development. Further, promising candidates for the 
inhibition of TRAP activity have been identified and characterized. 
 
Two compounds and structures with TRAP-inhibiting properties were provided. Both 
compounds inhibited TRAP activity and TRAP-dependent functions in the low micromolar 
range. By binding into the active site in different manners and displaying highly structural 
differences, they provide two independent fragments for structural optimizations as 
previously performed for the phosphonic acids [275–277]. Further experimental approaches 
are necessary to assess the selectivity and potency of the TRAP inhibitors, and to be able to 
extent its application to several (cancer) cell systems and in vivo models. In a next step, both 
analogs and the identified TRAP inhibitors can for example be tested in ex vivo cultured 
patient samples to assess their effect in a 3D-system. 
Studies on the molecular mechanisms of TRAP are detrimentally necessary to further 
understand and assess the involvement of TRAP in the disease. 
That TRAP might also have effects on other cancer cell hallmarks has been early noticed, 
when analyzing omics data and the phenotype of TRAP-overexpressing cancer cells. 
Specifically, TRAP seems to affect cancer cell metabolism and might play a role in cancer-
associated inflammation. Specific interest lies in the identification of the detailed role of 
TRAP isoforms in the interplay of the cancer microenvironment. Furthermore, the data on 
TRAP role on invasion and metastasis can be supplemented by in vivo mouse models. 
Molecular players identified by proteomic analysis revealed a strong connection and a 
possible context is reasonable to assess in a next step. The suggested involvement of TRIP-1 
in the recruitment and activation of TGFβ and CD44 signaling by TRAP could for instance 
be investigated in mechanistic studies.  
Furthermore, TRAP expression in cancer patient material can be completed by assessing the 
distribution of the TRAP isoforms, with a specific focus on TRAP 5b in cancer cells. The 
identification of unknown enzymes in the activation process of TRAP could further provide a 
possible targeting strategy for the tackling of TRAP-expressing cancers. 
 
Finally, TRAP has rendered an important and crucial target in the understanding of molecular 
changes introduced during cancer progression. Supported by a strong connection to earlier 
reported cancer-markers, it displays an interesting and potent candidate for research behind 
the goal of understanding cancer cell processes and patient-directed treatment. 
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Wir können alles sein. 
 
Woher wir kommen, ist nicht wichtig,  
wichtig ist, wohin wir gehen. 
Wir müssen nichts verstecken, 
wenn wir zu uns selbst stehen. 
Und wir können alles sein. 
 
Unsere eigenen Helden, unsere eigenen Freunde, 
unser eigener Investor in unsere eigenen Träume. 
Unsere eigenen Beschützer, unsere Schüler, unsere Lehrer, 
unsere eigenen Vorbilder, unser Halt, unsere Verehrer. 
Und wir können alles sein. 
 
Querdenker, Quereinsteiger, Grenzgänger, Wegweiser, 
Party People, große Kinder, Erfinder und Familiengründer, 
Alles-Erdachte-möglich-Macher, Lebenslauf-Collagenbastler, 
oder Master of Disaster an der Uni Kopenhagen. 
 
-- 
 
Grenzen sind Phantome. 
 
Gebaut von Angst. Bloß in Gedanken. 
Wenn du einmal um dich siehst, stehen da nirgends Schranken. 
Dein Weg ist frei, ganz bis zum Horizont, und bietet klare Sicht, 
nur gehen musst du alleine. Das übernimmt keiner für dich. 
Die beste Zeit ist immer jetzt. 
 
Julia Engelmann, Poetry-Slam 
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